Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 infection fatality rates in India: systematic review, meta-analysis and model-based estimation

Lauren Zimmermann, Subarna Bhattacharya, Soumik Purkayastha, Ritoban Kundu, Ritwik Bhaduri, Parikshit Ghosh, Bhramar Mukherjee
doi: https://doi.org/10.1101/2021.09.08.21263296
Lauren Zimmermann
1Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
2Center for Precision Health Data Science, University of Michigan, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Subarna Bhattacharya
3Department of Global Public Health, School of Public Health, University of Michigan, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soumik Purkayastha
1Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ritoban Kundu
4Indian Statistical Institute, Kolkata, West Bengal, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ritwik Bhaduri
4Indian Statistical Institute, Kolkata, West Bengal, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Parikshit Ghosh
5Delhi School of Economics, New Delhi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bhramar Mukherjee
1Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
2Center for Precision Health Data Science, University of Michigan, Ann Arbor, MI
6Department of Epidemiology, University of Michigan, Ann Arbor, MI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bhramar@umich.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction Fervorous investigation and dialogue surrounding the true number of SARS-CoV-2 related deaths and implied infection fatality rates in India have been ongoing throughout the pandemic, and especially pronounced during the nation’s devastating second wave. We aim to synthesize the existing literature on the true SARS-CoV-2 excess deaths and infection fatality rates (IFR) in India, through a systematic search followed by viable meta-analysis. We then provide updated epidemiological model-based estimates of the wave 1, wave 2 and combined IFRs using an extension of the Susceptible-Exposed-Infected-Removed (SEIR) model, using data from April 1, 2020 to June 30, 2021.

Methods Following PRISMA guidelines, the databases PubMed, Embase, Global Index Medicus, as well as BioRxiv, MedRxiv, and SSRN for preprints (accessed through iSearch), were searched on July 3, 2021 (with results verified through August 15, 2021). Altogether using a two-step approach, 4,765 initial citations were screened resulting in 37 citations included in the narrative review and 19 studies with 41 datapoints included in the quantitative synthesis. Using a random effects model with DerSimonian-Laird estimation, we meta-analyze IFR1 which is defined as the ratio of the total number of observed reported deaths divided by the total number of estimated infections and IFR2 (which accounts for death underreporting in the numerator of IFR1). For the latter, we provide lower and upper bounds based on the available range of estimates of death undercounting, often arising from an excess death calculation. The primary focus is to estimate pooled nationwide estimates of IFRs with the secondary goal of estimating pooled regional and state-specific estimates for SARS-CoV-2 related IFRs in India. We also try to stratify our empirical results across the first and the second wave. In tandem, we present updated SEIR model estimates of IFRs for waves 1, 2, and combined across the waves with observed case and death count data from April 1, 2020 to June 30, 2021.

Results For India countrywide, underreporting factors (URF) for cases (sourced from serosurveys) range from 14.3-29.1 in the four nationwide serosurveys; URFs for deaths (sourced from excess deaths reports) range from 4.4-11.9 with cumulative excess deaths ranging from 1.79-4.9 million (as of June 2021). Nationwide pooled IFR1 and IFR2 estimates for India are 0.097% (95% confidence interval [CI]: 0.067 – 0.140) and 0.365% (95% CI: 0.264 – 0.504) to 0.485% (95% CI: 0.344 – 0.685), respectively, again noting that IFR2 changes as excess deaths estimates vary. Among the included studies in this meta-analysis, the IFR1 generally appear to decrease over time from the earliest study end date to the latest study end date (from 4 June 2020 to 6 July 2021, IFR1 changed from 0.199 to 0.055%), whereas a similar trend is not as readily evident for IFR2 due to the wide variation in excess death estimates (from 4 June 2020 to 6 July 2021, IFR2 ranged from (0.290-1.316) to (0.241-0.651) %).

Nationwide SEIR model-based combined estimates for IFR1 and IFR2 are 0.101% (95% CI: 0.097 – 0.116) and 0.367% (95% CI: 0.358 – 0.383), respectively, which largely reconcile with the empirical findings and concur with the lower end of the excess death estimates. An advantage of such epidemiological models is the ability to produce daily estimates with updated data with the disadvantages being that these estimates are subject to numerous assumptions, arduousness of validation and not directly using the available excess death data. Whether one uses empirical data or model-based estimation, it is evident that IFR2 is at least 3.6 times more than IFR1.

Conclusion When incorporating case and death underreporting, the meta-analyzed cumulative infection fatality rate in India varies from 0.36%-0.48%, with a case underreporting factor ranging from 25-30 and a death underreporting factor ranging from 4-12. This implies, by June 30, 2021, India may have seen nearly 900 million infections and 1.7-4.9 million deaths when the reported numbers stood at 30.4 million cases and 412 thousand deaths (covid19india.org) with an observed case fatality rate (CFR) of 1.35%. We reiterate the need for timely and disaggregated infection and fatality data to examine the burden of the virus by age and other demographics. Large degrees of nationwide and state-specific death undercounting reinforce the call to improve death reporting within India.

INTRODUCTION

The second wave of SARS-CoV-2 in India–a country broaching 1/5th of the world population, wrought a devastating toll of an astronomical 414 thousand daily reported infections and 4.5 thousand reported daily deaths from COVID-19 (1) at its peak in May of 2021, leading to a collapse of healthcare infrastructure (2). Concerns have been raised regarding the inadequacy of the healthcare systems of adjacent countries in this region (3), as well as tragically realized amidst recent surges of SARS-CoV-2 in some of these countries (4).

It is now well-known that only a fraction of SARS-CoV-2 infections are captured, stemming from a large degree of covert infections, access, willingness and availability of testing, and sometimes a desire to maintain public image (5) (6). Similarly, due to incomplete and lagged reporting, lack of medical certification and misclassification of the cause of deaths, not all COVID-19 related deaths have been captured correctly (7) (8) (9). Infection fatality rates (IFR) are measured as the ratio of the total number of deaths to the total number of infections over a given period. Serological surveys, with rigorous sampling design and cogent analysis, can provide an estimate of the prevalence of antibodies (Ab) formed in response to a past natural infection, and thereby an estimate of the total number of infected cases in an unvaccinated study population, which forms the basis for the denominator of the IFR measure. With introduction of vaccines, seropositivity could arise both from vaccines or from past infections and thus such studies are less informative about the denominator in an IFR calculation. Excess deaths calculation using the death data released during the pandemic period can give us an idea on the number of COVID-19 deaths we failed to report or the extent of death underreporting (7) (9) (10). Compartmental epidemiological models, including extended versions of the susceptible-exposed-infected-removed (SEIR) model and renewal process models can also estimate the total number of latent infections and deaths by making stringent assumptions needed to identify certain key parameters (11) (12) (13).

From a global lens, several systematic reviews have examined this integral measure of SARS-CoV-2 mortality, the IFR, at various points of the pandemic. As of 16 June 2020, a systematic review and meta-analysis of 24 studies estimated a pooled worldwide IFR of 0.68% (95% CI: 0.53 – 0.82), while noting considerable heterogeneity among the included studies and being unable to adjust for age, comorbidities, and other demographic factors (limited by the availability of data) (14). Other efforts to systematically investigate the infection fatality rates of SARS-CoV-2 include a review and meta-analysis of age-specific IFRs from 27 studies among OECD countries (as of 18 September 2020), which concluded that the IFR increases substantially with age estimating an age-specific IFR of 0.002% among children aged <10, 0.01% among younger adults aged ≥25, 0.4% among adults aged ≥55, 4.6% among adults aged ≥65, and up to 15% among adults aged ≥85 (15). Limited to non-developing countries, this review estimated that 90% of the variation in IFR estimates is explained by the age make-up of the underlying populations (15). Regarding reconciling SARS-CoV-2 seroprevalence, a key ingredient to know IFR estimates, a systematic review and meta-analysis (as of 14 August 2020) of 47 studies (encompassing 23 countries worldwide) found a worldwide seroprevalence estimate of 3.38% (95% CI: 3.05-3.72) with a range of 0.37% (Malaysia) to 22.1% (Iran) among the included studies, and reported considerable overall heterogeneity among the included studies as well as regional variation in the effect size with 1.45% (95% CI: 0.95-1.84) for South America to 5.27% (95% CI: 3.97-6.57%) for Northern Europe (16). India was not examined in these multi-country systematic reviews of SARS-CoV-2 IFR and seroprevalence, and nor were any of its neighboring countries.

Concerning India and its neighboring countries (i.e., Bangladesh, Nepal, Pakistan, and Sri Lanka), certain features common in this region are distinct from the countries considered in the above reviews and thereby beckon a comprehensive investigation of the SARS-CoV-2 fatality within these countries. First, the age structures of these countries are relatively young in comparison to higher income countries (as of 2020, the estimated median age in years are the following: India 28.4, Bangladesh 27.6, Nepal 24.6(20), Pakistan 22.8, Sri Lanka 34.0 versus the United Kingdom 40.5, Italy 47.3, Germany 45.7, and the United States 38.3 (17)). Considering this difference in the population age composition, a meta-analysis of SARS-CoV-2 infection fatality rates and seroprevalence would aid in discerning the values of these measures specific to South-East Asia. We note that, at the time of this report, no systematic review has examined the existent studies on IFRs within the region encompassing and surrounding India.

Here, we perform a systematic review of existent literature on SARS-CoV-2 infection fatality rates (IFRs) in India and India’s neighboring countries of Bangladesh, Nepal, Pakistan, and Sri Lanka, as of 3 July 2021, with verification of search thoroughness extending to 15 August 2021. Due to the paucity of data and availability of relevant studies in the adjacent countries and considering the intensity of the latest SARS-CoV-2 outbreak in India as detailed above, we focused on India for the quantitative synthesis. Through a meta-analysis of SARS-CoV-2 IFR estimates, we examine the nationwide, regional, and state-specific estimates and heterogeneity over the course of the pandemic within India. As an alternative approach to empirical evidence synthesis and meta-analysis, we use an extended susceptible-exposed-infected-removed (SEIR) model to present updated estimates of SARS-CoV-2 infection fatality rates with data through June 30, 2021, as well as underreporting factors for cases and deaths, corresponding to the first and second waves, as well as cumulative, for COVID-19 in India. This paper concludes with a discussion of takeaways from the systematic review and meta-analysis, as well as from the updated model-based results. We highlight some immediate and future considerations regarding revising the death reporting system in India and why capturing deaths are important for the health and future of the living.

METHODS

Terminology and Definitions

Below we provide the definitions, with formulas as needed, of the various terms used throughout this systematic review and meta-analysis.

Seroprevalence survey (i.e., serosurvey) in the context of SARS-CoV-2 are large-scale studies aimed at estimating the true prevalence of SARS-CoV-2 (i.e., the cumulative percent infected over a period of time) within the target population utilizing serology testing for IgG or IgM antibody presence (18) scaled to the level of a geographic location (e.g., nationwide, statewide, citywide, or districtwide), a community, or a smaller group. Study designs of serosurveys commonly involve population-based sampling methods (e.g., multi-stage cluster sampling, probability proportionate to size, etc.) applied to obtain a randomly selected, representative sample.

Case Underreporting Factor (URF (C)) is defined as the estimated total cumulative infections divided by the reported (i.e., observed) cumulative cases at the indicated date. Embedded Image The numerator (estimated total cumulative infections) is estimated by the population of the target geographic region from which samples were selected, multiplied by the seroprevalence, as sourced from serosurveys. The population estimate is age-adjusted according to the age cut-off for the underlying study by multiplying the total population estimate of the study area by the proportion of the population in the age range included in the study sample.

Excess Deaths is defined as the absolute difference between the observed all-cause mortality in a specific time period and the expected all-cause mortality in the same period. When calculating excess deaths, the expected all-cause mortality is commonly projected using prior years of data, an average of prior years, or an alternative benchmark, as it largely depends on the availability and continuity of all-cause mortality data within the location of study. Embedded Image Death Underreporting Factor (URF (D)) is defined as the estimated total cumulative deaths divided by the reported (i.e., observed) cumulative deaths at the indicated date, as collected 14 days after the date indicated. Embedded Image The numerator of the URF (D) (i.e., estimated total cumulative deaths) is the location and time period-specific excess deaths estimate (available at the time of this report), as sourced from media reports and studies on excess deaths. Using all-cause-mortality to calculate excess deaths over a long period has the limitation that the numerator often is not specific to COVID-19 disease. Some model-based studies have alternative ways of estimating this fraction using assumed values of COVID-19 fatality rates.

Case Fatality Rate (CFR) is defined as the reported (i.e., observed) cumulative deaths divided by the reported/observed cumulative cases. Reported cumulative deaths are routinely collected 14 days after the date indicated to allow for fatality delay between symptom onset and death. Whereas reported cumulative cases are collected on the date indicated, as a conservative approach to capturing the cumulative infections up to the date indicated. Further details on the intuition behind the assumption of a 14-day fatality lag can be found in Supplementary Appendix F. Embedded Image Infection Fatality Rate1 (IFR1) is defined as the reported (i.e., observed) cumulative deaths (collected 14 days after the indicated date) divided by the estimated total cumulative infections. In other words, IFR1 is an estimate of the true fatality rate for which the uncertainty in the denominator is adjusted but not the uncertainty in the numerator, namely, death undercounting is not accounted for. Embedded Image In our meta-analysis, for studies without precalculated IFR1, the denominator (estimated total cumulative infections) is computed as the seroprevalence multiplied by the population estimate of the study location. Again, the population estimate is age-adjusted, according to the age inclusion criterion of the study design, by multiplying the population number by the percent of the population in the specified age range.

Infection Fatality Rate2 (IFR2) is defined as the estimated total cumulative deaths (14 days after the indicated date) divided by the estimated total cumulative infections. In other words, IFR2 is an estimate of the true fatality rate for which both the uncertainty in the denominator and the uncertainty in the numerator (i.e., death undercounting) are adjusted. Embedded Image For studies without precalculated IFR2, the denominator (estimated total cumulative infections) is the same as the denominator in IFR1. The numerator (estimated total cumulative infections) is computed as the reported (i.e., observed) cumulative deaths (collected 14 days after the indicated date) multiplied by the death underreporting factor, as either model-derived or sourced directly from media reports and studies on excess deaths.

Identification of Studies for Systematic Review and Meta-analysis

The present systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement and guidelines (19) (see Supplementary Appendix A for the completed PRISMA checklist). Two reviewers developed the search strategy with the expertise and guidance of information specialists from the University of Michigan Taubman Health Sciences Library. On July 3, 2020, we performed the search for relevant articles publicly disseminated from January 1, 2020 onwards and conducted in any language within the databases PubMed, Embase, World Health Organization’s database Global Index Medicus, as well as BioRxiv, MedRxiv, and SSRN through isearch, an interface that houses SARS-CoV-2 related reports curated by the National Institute of Health (a complete search strategy, including search terms, Boolean operators, and applied filters, for each database is published in Supplementary Appendix B). Up until August 15, we verified that no relevant studies were missed by manually combing through studies referenced in media reports, government press releases, and any additional preprints or reports published after July 3 and through August 15, 2021.

For the narrative review, eligible studies included a nationwide, regional (e.g., state, union territory, city, district, or slum designated area, etc.), or age/sex-specific measure of seroprevalence or infection fatality rate (IFR) for India or adjacent countries of Bangladesh, Nepal, Pakistan, and Sri Lanka. Consistent with a systematic review that examines international infection fatality rates of SARS-CoV-2 among OECD countries (i.e. non-developing countries) (15), studies were excluded in the full-text screening (a) if the studies examined narrower subpopulations of the location of interest (e.g., healthcare workers, HIV positive adults, or industrial workers, etc.), (b) if the studies recruited participants from certain facilities (e.g., blood donors, dialysis centers), (c) if the studies considered individuals at hospitals, urgent care centers, intensive care units (ICUs), or tertiary care centers, (d) if the studies performed active recruitment of subjects (i.e. participants volunteered), and (e) if the studies limited their cohort to asymptomatic or symptomatic individuals. These criteria are used to identify studies both with representative samples of the general population of interest and with measurements of the outcomes that reflect seropositivity of SARS-CoV-2 regardless of virus manifestation (or irrespective of clinical presentation and presence of symptoms).

For the meta-analysis of infection fatality rates (IFRs), studies were included if (in addition to meeting the eligibility criteria for inclusion to the qualitative review) (a) 95% confidence interval was available for either the seroprevalence and/or the precalculated IFR, when available, and (b) data on COVID-19 confirmed fatalities was available for the study location from covid19india.org (20) at the time of this review. Additionally, for studies that do not provide a precalculated IFR2 (i.e., do not provide an IFR estimate adjusted for death underreporting), a study was excluded from IFR2 examination if no excess deaths or death underreporting factors were available (at the time of this review) for the location of interest (e.g., district or city) in media reports or excess deaths focused publications. Namely, this report utilizes excess deaths from three sources for the nationwide meta-analysis of IFR2 (21) (22) (23) and the following sources for the regional and state-level IFR2 analysis: for cities and districts Ahmedabad (22), Bangalore Rural District (22), Chennai (22) (24), Indore (22), Mumbai (25) (22) (26), Ujjain (22), and for states Delhi (27) (13) (22), Karnataka (28) (29), Tamil Nadu (22) (28). Table A below summarizes the sources used in nationwide excess deaths studies (21) (22) (30) (23), as well as in the Data Development Lab (31), an interactive open source data platform recently made available for India.

View this table:
  • View inline
  • View popup
Table A.

Summary of data sources for nationwide excess deaths for India, as of June 2021, used in key

Two-Step Screening and Data Abstraction

Citation titles and abstracts were screened independently by two reviewers for verifying the inclusion and exclusion criteria. For articles not satisfying the exclusion criterion, the full text was accessed, and the two screeners separately reviewed the methods and results sections of these studies for final inclusion into this systematic review and meta-analysis. The two reviewers subsequently extracted data from the included articles on the following items: (a) study design, location, and time period, as well as inclusion criteria, (b) sample size denoting the number of participants in the study, (c) descriptive statistics of the proportion of the study cohort male versus female and the mean age of the study cohort, (d) estimate of infection fatality ratio (IFR) or seroprevalence for SARS-CoV-2 and corresponding 95% confidence intervals, when available, (e) any statistical sensitivity tests performed.

Statistical Meta-analysis

A detailed description of the meta-analysis framework is presented in Supplementary Appendix F. To perform the meta-analyses presented herein, the R package meta (33) was utilized and the R package metafor (34) was employed to perform the included sensitivity analyses.

In preparation for the meta-analysis, we extract the IFR or seroprevalence estimates, as well as the provided 95% CI, from each study corresponding to the study’s intended overall population. For seroprevalence studies without precalculated IFR1, we collect data on (a) COVID-19 confirmed fatalities from covid19india.org (20) 14 days after the end date of the study period (as previously reasoned), (b) 2019 projected population estimates from the World Bank for India (35), 2019 projected population estimates from the 2011 census for states (36), and 2011 census population estimates for districts and cities (limited by available projections) (36), (c) 2011 census information on age demographics for the study location (37), and (d) underreporting factors, as derived or directly reported from media reports and studies on excess deaths for the nation, state, district, or city were collected nearest to the end date of when the study was conducted. With these collected data items, for studies without a precalculated fatality rate, we compute IFR1 and IFR2 following the definitions provided in the Terminology and Definitions section above. We note that for smaller regional denominations (e.g., cities or districts) for which data on excess deaths were unavailable, we use the statewide death underreporting factor (if available) in computing IFR2.

For the meta-analysis itself, we estimate three versions of SARS-CoV-2 pooled IFRs– namely (a) IFR1, (b) IFR2 with lower limit of the reported estimates of URF (D), and (c) IFR2 with higher limit of the reported estimates of URF (D)– for each sub-analysis. First, using a random effects model with inverse variance method and DerSimonian-Laird (DL) estimation, we estimate the nationwide SARS-CoV-2 pooled IFRs, as well as 95% confidence intervals, for India across all available national IFR datapoints (both precalculated and computed herein) included in this review. Next, a regional analysis of IFRs is performed considering India partitioned into the following regions: North, Northeast, East, South, West, and Central. Regions with at least one available eligible study are examined. To compute the regional SARS-CoV-2 pooled IFRs, we first pool the IFR estimates from statewide, citywide, and districtwide studies associated with each state, using the same random effects estimation approach. Then, the regional SARS-CoV-2 pooled IFRs are approximated with the statewide pooled IFR estimates, using the analogous random effects model with the inverse variance approach and DL estimator.

In both the nationwide and regional analyses, heterogeneity is assessed using the I2 statistic, where a I2 of 50% to 90% denotes substantial heterogeneity and I2 ≥ 75% (and up to 100%) indicates considerable heterogeneity among the included studies, as recommended by Cochrane guidelines (38). For the regional analysis, we interpret the I2 with caution as we do expect there to be variation in the true effect size among the included studies, as these studies cover varying states and IFRs have been found to vary by state (13).

To assess publication bias, we produce a funnel plot to examine the distribution of p-values and 95% confidence intervals, as well as perform the Egger’s and Begg’s tests to formally test for funnel plot asymmetry. To assess the risk of bias in the seroprevalence estimates across the included studies, we utilized the Joanna Briggs Institute (JBI) approach (39) (40). Upon completing the series of questions for each study, the tool provides a rating of risk of bias (low/ moderate/ high) based on the sampling design and data collection methods. We answer each question according to the provided values (“Yes”/ “No”/ “Unclear”/ “Not applicable”). Remarks are included with respect to the IFR estimates within the returned strata of the risk of bias.

Model-based Estimation of Fatality Rates in India during Wave 1, Wave 2, and combined over waves from April 1, 2020 to June 30, 2021

The present study follows the same methodology as the previous versions (13). In brief, we employ a compartmental epidemiologic model, the extended susceptible-exposed-infected-removed (SEIR-fansy), to model the transmission dynamics of SARS-CoV-2. Accounting for the false negative rates of the SARS-CoV-2 antigen test type (e.g., RT-PCR and rapid antigen tests) observed in India, we include unascertained cases and deaths as a compartment. As depicted in Supplementary Appendix K Figure S1, the population is further divided into 10 disjoint compartments: S (Susceptible), E (Exposed), T (Tested), U (Untested), P (Tested Positive), F (Tested False Negative), RR (Reported Recovered), RU (Unreported Recovered), DR (Reported Deaths) and DU (Unreported Deaths). A full description of the methodological framework is available in Supplementary Appendix K. Nine differential equations form the basis for imitating the spread of SARS-CoV-2. Parameters and 95% credible intervals (CrI) are estimated using Bayesian techniques by performing Metropolis–Hastings algorithm-based random sampling from the posterior distribution with a Gaussian proposal density.

Considering the inherent differences between the first and second waves of the pandemic (e.g., the strain on the healthcare infrastructure and dearth of medical resources in wave 2), we examine the entailed epidemiological measures for wave 1 and wave 2 separately, with wave 1 as April 1 2020–January 31, 2021 and wave 2 as February 1, 2021–June 30, 2021 (latest until this report). The start date of wave 2 of February 1, 2021 is reasoned as two weeks before the national effective reproduction number crossed unity on February 14, 2021 to allow for time between virus exposure and symptom onset. Daily infected cases, recovered cases, and deaths are collected from covid19india.org (20). We compute nationwide and state-wise fatality rates and case–as well as death– underreporting factors for both wave 1 and wave 2. Additionally, we estimate cumulative infected case and death counts across waves 1 and 2 adjusting for the respective underreporting factors. To obtain the combined number of cases across both waves, we multiply the wave-specific infections with the underreporting estimate and sum across the two waves. Similarly, to obtain the combined number of deaths across both waves, we compute the combined number of deaths by multiplying the wave-specific deaths with the underreporting estimate and sum across the two waves. Lastly, an overall infection fatality rate (IFR) for India as of 30 June 2021 is provided as the estimated cumulative number of deaths divided by the estimated cumulative number of infections.

RESULTS

Search Results and Included Studies

As shown in Figure 1 below, the search resulted in a total of 5174 citations across the four search engines: PubMed (2940), Embase (1119), WHO Global Index Medicus (Southeast Asia Region: 5, Eastern Mediterranean Region: 2), and isearch (1078). After removing duplicate citations across databases, 4765 articles were screened in the initial level of title/abstract, and we reviewed 137 articles in the second level of full-text screening. Of these studies, 61 studies were excluded as no seroprevalence, nor infection fatality rate estimates were presented. Moreover, 18 studies were excluded as the cohort consisted of healthcare workers, 15 studies were excluded as the cohort consisted of patients from hospitals, urgent care units, or tertiary care centers, 5 studies were excluded because the cohorts were limited to either asymptomatic (4 studies) or symptomatic (1 study) individuals, 4 studies were excluded as the cohort consisted of working individuals, 2 studies were excluded as the cohort consisted of blood donors, 2 studies were excluded as the cohort was sampled from testing centers, 1 study was excluded because the cohort consisted of members from elderly care centers, 1 study was excluded as the participants were actively recruited. Overall, across these subpopulations, 48 studies were collectively excluded for the reason of having narrow or non-representative samples, which in turn impedes generalizability to the broader target population within the location of study.

Figure 1.
  • Download figure
  • Open in new tab
Figure 1. PRISMA flow diagram (41)

Qualitative Review

Locations of included articles

Of the 37 articles included in the narrative review, 2/5 countries originally in the search (namely, India and Pakistan) were present in these articles. In other words, no eligible studies were available for Bangladesh, Nepal, nor Sri Lanka. The predominant country studied was India (35/37 included articles) with Pakistan being the other country (2/37 included articles). In the initial screening, nearly all citations were written in English with 1 citation written in French. In the full-text screening, all articles were written in English.

Study designs, populations, and objectives

As shown in Supplementary Appendix C Table 1, among the 37 included articles, 27/37 were serosurvey studies (25 serosurveys for India (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) and 2 serosurveys for Pakistan (67) (68)) and 10/37 were other study designs (69) (70) (71) (72) (73) (74) (13) (12) (75) (76), such as extended compartmental epidemiological model-based approaches.

The age distributions of the study populations reflect the younger populations in India and Pakistan with 6/11 studies (that reported the study age composition) having a mean age of ≤24 to <40 years and 5/11 studies with a mean age of ≤40 to <50 years (Supplementary Appendix C Table 1). Regarding the participation rates by gender, out of the 19 studies (that reported the study gender composition) 5 studies had a considerably larger proportion of male than female participants, whereas 3 studies had a heavier percentage of female than male participants (Supplementary Appendix C Table 1). The remaining 11/19 had a comparable percentage of male versus female participants.

A nationwide target population accounted for 10/37 studies, namely, 8 for India (59) (60) (61) (62) (74) (13) (12) (75) (76) and 1 for Pakistan (68). The predominant population of interest was cities with 19/37 studies focusing on municipal target populations and with the following counts of studies per city: 6 Delhi–India (47) (48) (49) (50) (70) (71), 4 Mumbai–India (56) (57) (58) (73), 1 Ahmedabad–India (42), 2 Bhubaneswar–India (44) (45), 2 Chennai–India (46) (69), 1 Indore–India (55), 1 Pimpri-Chinchwad–India (63), 1 Ujjain–India (66), and 1 Karachi–Pakistan (67). The next highest population of interest was state and union territories with 6/37 studies focusing on statewide generalizations and the following counts of studies per state or union territory: 3 Karnataka–India (52) (53) (72), 1 Kashmir–India (54), 1 Puducherry–India (64), and 1 Tamil Nadu–India (65). The prevalence of SARS-CoV-2 in slum dwellings was considered in 8/37 studies with the following counts of studies per slum area: 3 slum sections within Mumbai–India (56) (57) (73), 1 slum sections within Matunga, Chembur West, and Dahisar wards in Mumbai– India (58), 1 Devarajeevana Halli (DJ Halli) slum in Bengaluru–India (51), 1 slum sections within Pimpri-Chinchiwad–India (63) and 2 nationwide slum prevalence approximations from the 2nd and 3rd nationwide serosurveys for India (60) (61). Seroprevalence of SARS-CoV-2 within rural districts versus urban was examined in 9/37 included studies and with the following counts per area: 1 Bangalore Rural District (with subdistricts–otherwise referred to as taluks of Devanahalli, Doddaballapura, Hoskote, Nelamangala)–India (43), 1 Delhi–India (50), 1 Karnataka–India (52), 1 Kashmir–India (54), 1 Puducherry–India (64), 1 Tamil Nadu–India (65) and 3 nationwide–India (59) (60) (61).

SARS-CoV-2 surveillance measurements and levels of granularity

As presenting either an IFR or seroprevalence estimate was an inclusion criterion, all 37 included studies estimated one or both of these measures. The breakdown of measures examined was as follows: 8/37 studies presented only IFR estimates without estimating seroprevalence, 15/37 studies presented only seroprevalence estimates without computing IFRs, and 14/37 studies reported both estimated seroprevalence and IFRs. Among the included studies, seroprevalence was estimated at the following levels: overall region, subregion (e.g., district/ward), type of residence (e.g., urban/rural/slum/non-slum), age, sex, age-sex, and for select comorbidities (e.g., diabetes and hypertension). In contrast, IFRs were estimated largely at the overall level with just 2 studies presenting age-sex stratified estimates (1 serosurvey for Tamil Nadu (65) and 1 other study design for Karnataka, Mumbai and Bihar migrants (72)).

Remarks on excluded articles

The prevailing reason for exclusion of studies in the full-text screening was that the article did not provide concurrent prevalence estimate nor an IFR (61/109). Of these 61 studies presenting other epidemiological measures, a large number examined CFRs. Additionally, a considerable number of studies (18/109) were excluded that examined the subpopulation of healthcare workers and with the following counts of healthcare worker studies per country: India (16) and Pakistan (2). The third notable exclusion criterion was studies that examined hospital, urgent care, or tertiary care centers (15/109), which resulted in the following counts of patient or hospitalized studies per country: India (11), Pakistan (2), Bangladesh (1), and Nepal (1). A complete list of studies excluded with reasonings is presented in the Supplementary Appendix D, as well as a summary table synthesizing the total number of studies excluded per eligibility criterion by country (see Supplementary Appendix E).

Quantitative Summary for India: Meta-analysis of Infection Fatality Rates (IFR)

Of the 37 eligible studies in the narrative review, 19 and 17 studies were included in the meta-analysis of IFR1 and IFR2, respectively. Supplementary Appendix G lists the studies that were not able to be included in the meta-analysis and each respective reason for exclusion. To summarize, the reasons for exclusion include: (a) did not provide a 95% confidence interval for the seroprevalence and/or IFR estimate, (b) fatality data were unavailable for the study location (e.g., city or select districts) from covid19india.org (20), (b) excess deaths data were unavailable at the state level for the study location in order to derive the death underreporting factor, (d) studies in Pakistan as previously discussed the meta-analysis focuses on India, and (e) studies that stratify by slum versus non-slum and do not provide an overall estimates are excluded, as individuals living in slum areas tend to be of low socioeconomic status relative to persons in non-slum areas.

Summary of Nationwide Underreporting of Infections

As shown in Table 1 below, the breadth of case underreporting countrywide has remained high in wave 2 compared to wave 1, as is evidenced by the dip in case underreporting factors (URF) from 29.1 to 14.3 in the 1st to the 2nd nationwide serosurveys compared to the consistency in high case URFs from 25.7 to 24.9 in the 3rd and 4th nationwide serosurveys, respectively, in India (59) (60) (61) (62). Please note that the 4th serosurvey did include vaccinated individuals, but by June 30, only roughly 5% of the Indian population was fully vaccinated and under 20% were partially vaccinated, so the estimates reflect largely antibodies from past infections but are likely overestimates.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Nationwide seroprevalence and case underreporting factors for India.

Background on Nation and State Level Excess Deaths

As shown in Table 2, five recent studies have provided nationwide excess deaths estimates for India, as of June 2021 (21) (32) (22) (30) (23). Of the three studies that examine excess deaths in India broken out by waves 1 and 2 (21) (22) (23), excess deaths are generally found to be considerably higher in wave 2 than wave 1 with the exception of the Anand et al., 2021 study (23), where excess deaths decrease from 3.4 (wave 1) to 1.5 million (wave 2). We note that the time period of the second wave in this study (23) extends into wave 2, as the national effective reproductive number crossed unity on February 14, 2021 in India, which may in part explain the high excess deaths estimate comparable to the other two studies. The degree of nationwide death underreporting has remained high from waves 1 to 2 with the Wave 1 URF (D) ranging from 3.8-19.6 and the Wave 2 URF (D) ranging from 4.0-11.2 (Table 2). Up to June 2021, the cumulative excess death estimates across waves 1 and 2 for India range from 1.79 million (21) to 4.9 million (23), suggesting a combined nationwide URF (D) of 4.4-11.9.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 2.

Nationwide excess deaths and death underreporting factors for India in waves 1, 2, and combined.

As shown below in Table 3, the statewide excess deaths available at the time of this report largely show a similar story of increased excess deaths in wave 2 relative to wave 1, corroborating the severe toll of the second wave of the pandemic on India. In parallel, the state-specific death URFs are consistently higher in wave 2 compared to wave 1 (Table 3), actualizing the widely discussed absence and deterioration of timely and accurate death reporting in wave 2 in various states in India. The exception to this assertion is Kerala where the wave-specific death URFs are not meaningful different and excess deaths have remained low or albeit negative (Table 3). In wave 1, the two states with the highest death URFs are Assam (14.1-19) and Andhra Pradesh (9.1-11.1), whereas the two states with the lowest death underreporting that in fact exhibited negative excess deaths compared to prior year(s) are Gujarat (−70 thousand deaths) and Uttar Pradesh (−37 thousand deaths). In wave 2, the two states with the largest death underreporting are Madhya Pradesh (23.8-42.4) and again Andhra Pradesh (24.6-36.2). The two states with the lowest death URFs in wave 2, where excess deaths were lower than the number of reported COVID-19 deaths, are Kerala and Delhi. It is important to recognize that the timing of the onset of the second wave differs by state and city, wherein Table 3 the categorization of waves is based on the timing of the second wave nationwide in India.

View this table:
  • View inline
  • View popup
Table 3.

Statewide excess deaths and death underreporting factors for India in waves 1, 2, and combined.

Nationwide IFR1 and IFR2

Figure 2 presents the results of the nationwide meta-analysis of IFR1 for India. Using a random effects approach with DL estimation, the estimated nationwide pooled SARS-CoV-2 IFR1 for India is 0.097% (95% CI: 0.067 – 0.140). This suggests a nationwide SARS-CoV-2 fatality ratio for India of 97 deaths per 100,000 infections, when not accounting for underreporting of deaths. As seen in Figure 2, there is considerable variation in the time periods encompassed in the studies belying this overall estimate. The range of IFR1 (from highest to lowest) among the included studies is 0.199% (4 June 2020) to 0.055% (6 July 2021).

Figure 2.
  • Download figure
  • Open in new tab
Figure 2. Nationwide estimated pooled IFR1 of SARS-CoV-2 for India.

Note: * = IFR1 precalculated. ** = IFR2 precalculated. *** = both IFR1 and IFR2 precalculated. For those with no stars, IFR1 and IFR2 as well as 95% CIs were computed.

Figure 3 shows the results of the nationwide meta-analysis of IFR2 for India. Using a random effects approach with DL estimation, the estimated nationwide pooled SARS-CoV-2 IFR2 for India ranges from 0.365% (95% CI: 0.264 – 0.504) to 0.485% (95% CI: 0.344 – 0.685), when applying the lower and higher ends of the uncertainty bracket for death underreporting, respectively. This can be interpreted as a nationwide SARS-CoV-2 fatality ratio for India of 365-485 deaths per 100,000 infections, when further adjusting for underreporting of deaths.

Figure 3.
  • Download figure
  • Open in new tab
Figure 3. Nationwide estimated pooled IFR2 of SARS-CoV-2 for India, with lower and higher URF uncertainty.

Note: * = IFR1 precalculated. ** = IFR2 precalculated. *** = both IFR1 and IFR2 precalculated. For those with no stars, IFR1 and IFR2 as well as 95% CIs were computed.

A detailed forest plot of the nationwide seroprevalences of SARS-CoV-2 in India, as well as the accompanying 95% confidence interval, underlying the computed nationwide IFRs, as directly reported in the included studies, can be found in Supplementary Appendix H Figure 1.

With respect to observed time trends from this meta-analysis, Table 4 includes a comparison of the case fatality rate (CFR) to IFR1 and IFR2 in waves 1 versus combined across waves 1 and 2. Both the CFR (i.e., not accounting for case nor death underreporting) and IFR1 (i.e., not accounting for death underreporting) have decreased overtime. Specifically, the nationwide CFR has decreased from 5.56% in June 2020 to 1.36% in July 2021 (Table 4). The nationwide IFR1 has also largely been decreasing over time from 0.199% (4 June 2020) to 0.055% (6 July 2021), based on estimates (both precalculated and computed) from included studies (Table 4). Whereas for IFR2 (i.e., when adjusting for both case and death undercounting) this trend is not readily apparent. As a whole, IFR2 has changed overtime between 0.290% (4 June 2020) to 0.241-0.651% (6 July 2021), oscillating between 0.241% (6 Jan 2021) to 0.916-1.316% (4 June 2020), as detailed in Table 4. The absence of this trend for IFR2 reconciles with the large excess deaths estimates observed for wave 2 compared to wave 1 (Table 2) and, in particular, the increase in the nationwide death URFs of 3.8-4.2 (wave 1) to 10.1-11.2 (wave 2) (Table 2), as derived from the excess deaths estimated in Deshmukh et al., 2021 (22).

View this table:
  • View inline
  • View popup
Table 4.

Comparison of nationwide CFR to IFR1 and IFR2 from included studies for wave 1 and across waves.

Regional and Statewide IFR1 and IFR2

Detailed estimates of regional pooled IFR1 and IFR2 of SARS-CoV-2 in India and 95% confidence intervals (CI), as well as the statewide pooled IFR1 and IFR2 estimates inputted for each region, are presented in Figures 4 and 5, respectively. Using the same random effects model with DerSimonian-Laird estimation as in the nationwide analysis, the regional pooled IFR1 is estimated to be the following (as ordered from highest to lowest pooled effect size and reporting only regions with more than one state): East 0.136% (95% CI: 0.062 – 0.302), West 0.125% (95% CI: 0.052 – 0.303), North 0.109% (95% CI: 0.037 – 0.325), and South 0.062% (95% CI: 0.023 – 0.164) (Figure 4). Hence, East and West India have the largest estimated IFR1 of 0.136% and 0.125%, respectively, suggesting estimated infection fatality rates (when not adjusting for underreporting) for SARS-CoV-2 of 136 deaths per 100,000 persons and 125 deaths pers 100,000 persons in these regions, respectively. The estimate for the East is largely driven by the comparatively high statewide IFR1 estimate for West Bengal of 0.322% (95% CI: 0.290 – 0.357), whereas the estimate for the West is driven by Maharashtra (0.244%) (Figure 4). The lowest IFR1 estimate is for South India of 0.062 (95% CI: 0.023 – 0.164), backed by the Andhra Pradesh and Karnataka which have the lowest statewide pooled IFR1 of 0.019% and 0.019%, respectively (Figure 4). Also considering regions with 1 state, pooled regional IFR1 estimates range from 0.062 for South to 0.174% for Central.

Figure 4.
  • Download figure
  • Open in new tab
Figure 4. Regional estimated pooled IFR1 of SARS-CoV-2 for India.

Note: * = IFR1 precalculated. ** = IFR2 precalculated. *** = both IFR1 and IFR2 precalculated. For those with no stars, IFR1 and IFR2 as well as 95% CIs were computed.

Figure 5.
  • Download figure
  • Open in new tab
Figure 5. Regional estimated pooled IFR2 of SARS-CoV-2 for India, with lower and higher URF uncertainty.

Note: State-specific IFRs in this forest plot are pooled estimates across included studies encompassed in each state.

We also find considerable heterogeneity exists even within each respective region in India. As examples, the statewide pooled IFR1 varies in the North from 0.043% (Jammu and Kashmir) to 0.362% (Punjab), in the South from 0.019% (Andhra Pradesh and Karnataka, respectively) to 0.162% (Puducherry), and in the West from 0.051% (Goa) to 0.244% (Maharashtra).

Using the same random effects model with DL estimation, the range of the regional pooled IFR2 is estimated to be the following (as ordered from highest to lowest pooled effect size and considering only regions with >1 state): North 0.477% (95% CI: 0.250 – 0.911) to 0.477% (95% CI: 0.250 – 0.911), West 0.396% (95% CI: 0.294 – 0.534) to 0.399% (95% CI: 0.297 – 0.535), East 0.304% (95% CI: 0.153 – 0.605) to 0.304% (95% CI: 0.153 – 0.605), and South 0.191% (95% CI: 0.165 – 0.223) to 0.205% (95% CI: 0.175 – 0.241) (Figure 5). Hence, North and West India have the largest estimated IFR2 of 0.477-0.477% and 0.396-0.399%, respectively, indicating estimated infection fatality rates (when adjusting for death underreporting) for SARS-CoV-2 of 477 deaths per 100,000 persons and 396-399 deaths per 100,000 persons in these regions, respectively. The Northern IFR2 estimate is largely driven by the comparatively high statewide IFR2 estimate for Punjab (1.010%) which has the second highest statewide pooled IFR2 (after Madhya Pradesh at 1.061%) of all states encompassed among the included studies, whereas the estimate for the West is driven by Gujarat (0.607%) (Figure 5). The lowest IFR2 estimate is again for South India of 0.191-0.205% (among regions with >1 state), backed by Karnataka and Kerala which have the lowest statewide pooled IFR2 of 0.067-0.083% and 0.144%, respectively (Figure 5). In sum, when considering regions with 1 state, pooled regional IFR2 estimates range from 0.168% for Northeast to 1.061% for Central.

A detailed forest plot of the state, city and district-specific seroprevalences of SARS-CoV-2 in India, as well as the accompanying 95% confidence interval, belying the computed regional and statewide IFRs, as directly reported in the included studies, can be found in Supplementary Appendix H Figure 1.

Key Findings

  • ✤ Regional pooled IFR1 estimates within India range from a low of 0.062% in the South to a high of 0.136% in the East. Regional pooled IFR2 estimates range from [0.191 – 0.205%] in the South to [0.477%] in the North.

  • ✤ Considerable within region heterogeneity is also observed, as pooled state specific IFR1 and IFR2 estimates are evidenced to vary within regions.

We present a funnel plot of the standard error of the effect sizes of the included studies in Figure 6 as a standard method for examining publication bias. Although the results show asymmetry, in the context of seroprevalence proportions from serosurveys, which comprise the bulk of the study designs, this does not necessarily indicate the presence of publication bias (79). Instead, we suspect that the asymmetry is due to heterogeneity in the actual effect sizes of the prevalence of SARS-CoV-2 among the populations captured by the included studies. A detailed assessment of publication bias is presented in Supplemental Appendix J. The results of the Joanna Briggs Institute (JBI) assessment for risk of bias within each included study can be found in Supplemental Appendix I.

Figure 6.
  • Download figure
  • Open in new tab
Figure 6.

Funnel plot for examination of publication bias across included studies.

Data files and code used to produce the above results are available on GitHub at the following repository: https://github.com/lzimmermann4/india_c19_ifrs.

Updated Model-based estimates of Wave 1 and Wave 2 Fatalities

Since wave 1 is defined analogously as in the latest report (13) and the underlying data are the same, the wave 1 estimates presented herein are unchanged. Briefly, when adjusting the denominator by the estimated cases underreporting factor of 11.11 (95% CrI 10.71 – 11.47), the nationwide IFR1 estimate (defined as observed cumulative deaths/estimated total cumulative infections) for wave 1 is 0.129% (95% CrI 0.125 – 0.134). When further adjusting the numerator by the estimated death underreporting factor of 3.56 (95% CrI 3.48 – 3.64), we obtain a nationwide IFR2 estimate (i.e., estimated cumulative total deaths/estimated cumulative total infections) for wave 1 of 0.461% (95% CrI 0.455 – 0.468). The wave 1 IFR2 estimate is largely congruent to the estimated effect sizes from the latest nationwide serosurvey in India (59) in that it falls within the bounds of the computed IFR2 herein for the 4th nationwide serosurvey of 0.241-0.651%, when applying a death underreporting factor range of 4.4 (1.79 million excess deaths (21)) to 11.9 (4.9 million excess deaths (23)).

Since wave 2 data extend to June 30, 2021, using the same compartmental epidemiological model we estimate case and death underreporting factors of 13.3 (95% CrI 11.4 – 14.6) and 3.46 (95% CrI 3.13 – 3.69), respectively. As such, the nationwide IFR1 estimate for wave 2 is 0.095% (95% CrI 0.086 – 0.109), which is slightly higher than the previously reported estimate of 0.032% (95% CrI 0.029% – 0.035%) as of May 15, 2021 (i.e. near the peak of wave 2 in India) (13). The nationwide IFR2 estimate for wave 1 is 0.326% (95% CrI 0.316 – 0.342), which is higher than our latest reported estimate of 0.183% (95% CrI 0.180 – 0.186) as of May 15, 2021 (13). The current estimates of the IFR for wave 2 have increased in magnitude in comparison to than past estimates due to having a time period that better reflects the trajectory of the second wave and data that encompass both the ascent and descent of cases and deaths. Moreover, the updated underreporting factors for cases and deaths are half the size of previous underreporting factors for wave 2 (i.e. 26.73 (95% CrI 24.26 – 28.81) and 5.77 (95% CrI 5.34 – 6.15), respectively, as of May 15) (13) and have largely converged in magnitude to the underreporting factors for wave 1.

Figure 6 contains the case and death underreporting factors and estimated number of infections and deaths for waves 1 and 2, respectively, for India. State-level estimates of IFR1 and IFR2 for waves 1 and 2 are reported in Supplementary Appendix N Figure 2, which shows the between state variation in these measures for wave 1 and wave 2, respectively, for the 20 states with high cases-deaths within India.

Figure 6.
  • Download figure
  • Open in new tab
Figure 6.

Comparison of observed and estimated case and death counts and corresponding underreporting factors from wave 1, wave 2 and both combined.

Combined estimates across the waves

As shown in Figures 6 above, the total cases (reported and unreported) is estimated to be 381.6 million and the total deaths (reported and unreported) to be 1.4 million, across waves 1 and 2 for India. Subsequently, the combined infection fatality rate (IFR) across both waves is estimated to be 0.101% for IFR1, and 0.367% for IFR2 (as previously defined). State-level case and death underreporting factors for India are included in Supplementary Appendix N Tables 1-3 and Figure 3.

We also include a state and country level comparison of the estimated case underreporting factors across both waves to the estimated case under counting factors presented by ICSM in the 4th nationwide seroprevalence survey (as of May 31, 2021) for India (59) (see Supplementary Appendix N Table 4). Briefly, the estimated case underreporting factors presented herein are lower at large than the case undercounting factors announced for the 4th nationwide seroprevalence survey (59), with the exceptions of Andhra Pradesh, Chhattisgarh, Jammu and Kashmir, and Kerala where the case underreporting factors that we estimate are larger, as well as Maharashtra where the case underreporting factor is the same. As such, we present estimated case underreporting factors that are conservative with respect to the recent nationwide serosurvey under counting estimates. The true extent of the magnitude of infections absent in reported case counts is wagered to lie somewhere in between.

Key Findings

  • ✤ As of 30th June 2021, nationwide URF (C) and URF (D) are estimated to be 12.5 and 3.5, respectively by the SEIR model.

  • ✤ Nationwide SEIR model-based estimated total cumulative infections is 381.6 million and estimated total cumulative deaths is 1.4 million (as of 30th June 2021), whereas reported deaths were 412 thousand and cases were at 30.4 million.

  • ✤ Nationwide model-based cumulative IFR1 and IFR2 estimates are 0.101% (95% CI: 0.097 – 0.116) and 0.367% (95% CI: 0.358 – 0.383), respectively.

  • ✤ The magnitude of these model-based estimates largely reconcile with the empirical findings. Across empirical data and model-based estimation, IFR2 is nearly 3.6 times the size of IFR1.

DISCUSSION AND CONCLUSIONS

Neighboring Countries

Despite there being insufficient data and sparse eligible studies in the neighboring countries, a brief snapshot into the SARS-CoV-2 situation within each country shows that the case fatality rate (unadjusted for underreporting) in neighboring countries is at par with India, if not higher. In Table 5, we provide a comparison of nationwide CFRs, as of 31 July 2021, within each of the countries included in this review (i.e., India, Bangladesh, Nepal, Pakistan, and Sri Lanka). Of these five countries, Pakistan stands out as having the highest CFR at 2.37% with 1.02 million cumulative reported infections and 24 thousand cumulative reported deaths (31 July 2021). Whereas India in fact has the lowest CFR of these 5 countries at 1.36%, but less surprisingly given its large population has the highest reported death and confirmed infection toll of 430 thousand and 31.6 million (31 July 2021), respectively. We recognize and caution that the CFR is an imperfect measure of the true SARS-CoV-2 fatality rate and that levels of underreporting of deaths and cases vary by country (8). In sum, Table 5 also presents a CFR across the countries included in this systematic review which is 1.42% to summarize the observed mortality rate in this region. The CFR among the neighboring countries alone is 1.96% which indicates that the SARS-CoV-2 observed mortality rate of the neighboring countries appears to be similar to that of India, if not slightly higher (whilst cautioning the fog of undercounting).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 5.

Comparison of nationwide CFRs among countries in review, as of July 2021.

Summary on fatality rates in India

For India, there were enough eligible studies to perform a meta-analysis of infection fatality rates. A key result of the meta-analysis concerning the nationwide IFR estimates for India is that both the CFR (i.e., not accounting for infection nor death underreporting) and IFR1 (i.e., not accounting for death underreporting) have decreased over time, whereas IFR2 appears to have remained same or even increased in some studies over time. In other words, when failing to take into account case and/or death underreporting (i.e., CFR and IFR1), the SARS-CoV-2 mortality rate falsely appears to be decreasing. However, when correctly adjusting for both underreporting of infections and deaths (i.e., IFR2), we do not observe that less deaths are resulting from the same number of infections through wave 2 compared to wave 1. This aligns with the catastrophic collapse of the healthcare system observed at large in India during the second wave of the pandemic (2). In sum, use of either the CFR or IFR1 (not accounting for death underreporting) alone may be deceptively misleading, and IFR2 should also be utilized in public health programming and policy decision making.

The narrative review of general population SARS-CoV-2 infection fatality rate or seroprevalence studies brought forth some trends concerning virus spread and fatality. In India, dense urban areas and slum dwellings have been found to have markedly higher prevalence rates in comparison to non-slum or rural locations (e.g., 58.4% (95% CI: 56.8– 59.9) among slums versus 17.3% (95% CI: 16.0–18.7) for Mumbai (58) among non-slums, and 57.9% (95% CI: 53.4–62.3) among a slum in Bengaluru (51)). Trends in the infection fatality rates (IFRs) are less obvious among the albeit limited number of slum population-focused seroprevalence studies in this region. A study in Mumbai found the IFR of SARS-CoV-2 in slums to be one-third the size of that of non-slums (i.e. 0.076% among slums versus 0.263% among non-slums (58)). Similarly, another study on a slum in Bengaluru estimated the IFR to be 2.94 deaths per 10,000 infections (or 0.029%) (51).

When estimating regional and statewide IFR estimates for India, the latest available studies for certain regions was during the outset of the pandemic (e.g., Central India with both input studies around August 2020). Such variation in study time periods highlights the need for updated seroprevalence studies in select regions. The findings from this regional meta-analysis also underscore the geographical differences in data collection/research spread across India. A large number of the included studies in this systematic review and meta-analysis were in the South and North, with substantially less coverage in the Central and Northeast regions. Moreover, no eligible serosurveys were available for the region Northeast India (which includes the following states: Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Sikkim and Tripura). This leads us to the limitations of the meta-analysis presented herein.

Limitations of Meta-analysis

We were not able to incorporate Bangladesh, Nepal, Pakistan, nor Sri Lanka in the meta-analysis presented in this paper as no eligible studies were available for these countries (aside from Pakistan, which had 2 included seroprevalence surveys), as previously discussed in the Results section. There were insufficient age-as well as sex-disaggregated IFRs for India (and for the neighboring countries) to examine heterogeneity in IFR estimates by either demographic. Furthermore, although age and sex-disaggregated seroprevalence estimates were extracted from the included studies, disaggregated deaths and cases by these demographics are not available for India nor for its states, cities, nor districts, at the time of this review. Additionally, there were insufficient data on excess deaths for select states (e.g., Jammu and Kashmir and Puducherry) that precluded our ability to compute IFR2 for studies encompassed in these states and, as such, we were unable to include these studies in the meta-analysis for the regional IFR2. Additionally, we caution that several of the included studies in the quantitative synthesis are in the process of being peer-reviewed, and so multiple underlying datapoints have not yet been verified.

Lastly, we note that global studies that examine India along with multiple other countries (as part of a country level global analysis) but do not explicitly refer to India in the title/abstract would not be captured by our published search strategy. Therefore, a limitation of the meta-analysis is that these IFR estimates for India from global studies are not comprehensively reflected in the empirical results of IFRs and similarly in the excess deaths synthesis. For example, a recent study by Rahmandad et al. (2021) (82) that appears (exact estimates are not reported) to estimate for India a ratio of estimated to reported deaths on the log scale in the ballpark of 1.2-1.5 (i.e. 3.3-4.4 when exponentiated) and an IFR near 0.4-0.5% for India (as of 22 December 2020), as part of a global analysis of 92 nations, was not captured (no explicit reference to India in title/abstract). Hence, this is an example of model-based estimates not reflected in the empirical findings evidenced in this report.

Recommendations moving forward

Based on the empirical and model-based findings evidenced in this report, we provide some high-level recommendations, primarily, as it concerns India. To reiterate, investigations aimed at estimating the true extent of COVID-19 attributed deaths in India have relied on a myriad of data sources (Table A). Such data sources do not come without their challenges (e.g., non-response bias and selection bias), and often lead to considerable variation in the ultimate results. For example, Ramachandran and Malani (2021) provide a higher estimate of excess deaths for India of 5.21 million (compared to their 3.36 million excess deaths estimate) for January 2020 to June 2021, when further considering households that do not respond consecutively (30). Given that no current all-cause mortality data exist for India at the time of this report with the latest release in 2010-2013, linking data sources in this manner is a common alternative. We encourage the release of timely and disaggregated data on SARS-CoV-2 cases and deaths, as are needed to assess stratified effects by age-sex-geography(5). Despite geographic heterogeneity, quality of case and death reporting remains of great concern for India and continues to mask the true fatality rate as well as impede ongoing epidemiological investigations. In the absence of all-cause and disaggregated COVID-19 mortality data, tools (e.g., a personal digital health identifier) (5) and fortified vital surveillance methods (e.g., monitoring inactive bank accounts) and practices (e.g., increased community engagement) (5) are needed to facilitate and validate the use of the previously mentioned data sources and others. Strengthening the nationwide vital surveillance system in these ways would enable timely and pointed interventions from public health and government officials to ultimately prevent further overload of healthcare systems and loss of life. To put the excess deaths synthesis into context, the range of death underreporting factor for India of 4.4-11.9 (based on 1.79-11.9 million excess deaths from (21) and (23), respectively) falls toward the higher end of the global death undercounting factor of 3.3 (95% CI: 2.1-4) estimated by the Economist (as of May 2021) (83). This indicates that the extent of death underreporting, as it pertains to SARS-CoV-2 remains particularly acute for India as compared to that of globally.

Why death matters?

From an economic perspective, why is it necessary to do these mortality calculations? Death matters because life matters – prolonging life is a goal, not merely a means to generate economic value. The widely used human development index (HDI) of the World Bank takes a multi-dimensional approach to measuring welfare. Material wellbeing (GDP) is only one of its three components; the others involve knowledge (literacy rate) and life (life expectancy at birth).

Nevertheless, for the purpose of cost-benefit analysis and economic evaluation of public health measures, it is useful to be able to assign a monetary value to every life lost or saved. Measuring the value of a life by lost earnings or productivity is deeply flawed – it would, for example, have the absurd implication that the lives of non-working individuals have no value at all. The most commonly used approach to estimating the value of a statistical life (VSL) adopts the revealed preference or willingness-to-pay (WTP) principle. Hedonic wage regressions estimate the compensating differential (84) in market wages for jobs that involve a higher probability of fatal accidents – a measure of how much income the average worker is willing to sacrifice in order to reduce mortality risk. Sacrificed earnings are then aggregated over the lifetime using present discounted values and scaled up to a probability of 1 to arrive at VSL.

There are several estimates of VSL from developed countries1 but studies on developing countries including India are few and far between. For our purposes, we will use Majumder and Madheswaran (2018) (85) who estimate VSL for the average male industrial worker in India to be INR 44.69 million (US $0.61 million at current exchange rates)2. This may introduce upward as well as downward biases into our calculations. For example, people dying of COVID-19 are, on average, older than the industrial workforce, which implies the mortality cost presented below is an overestimate. On the other hand, wages are only one part of a worker’s economic contribution. A proper accounting of the social value of a life must also account for profits, rents and consumers’ surplus generated by the economic activity of that individual, as well as non-pecuniary benefits conferred on relatives, friends and acquaintances. These are not reflected in private WTP and are therefore a source of underestimating VSL. The calculations presented below are ballpark figures that will reflect reality closely if the above-mentioned biases largely cancel each other out.

Table 6 below monetizes the death toll of COVID-19 in India till June 2021. Based on reported death figures alone, the economic cost of Covid-induced mortality comes to around 9% of India’s annual GDP. If we use the model-based estimates or the lower end of the range of excess death estimates, we incur a notional cost of 30-40% of annual GDP. Note that the official decline in India’s GDP in the fiscal year 2020-21 is 7.7%, which is a gross underestimate of the true loss once the value of lives is taken into account. By various estimates, the fiscal outlay of the government in its financial rescue package was about 1% of GDP. This is a very small fraction of what is at stake in this pandemic. Total healthcare spending in 2018 by the central and state governments taken together was only 1.28% of GDP, which again illustrates the serious under-investment in mitigating health shocks like COVID-19.

View this table:
  • View inline
  • View popup
Table 6.

Summary of economic cost estimates attributed to SARS-CoV-2 death toll in India, as of June 2021.

Other than national estimates of mortality and IFR, there is considerable value to measuring infections and deaths across gender, caste, income levels, regions, etc. These can be useful guides for policymakers, telling them where scarce healthcare resources and aid should be concentrated. The within-country heterogeneity in both the epidemiological and economic impact of the disease has been noted in studies from all parts of the world. Unfortunately, absence of disaggregated data has tied the hands of researchers in India. Nevertheless, our meta-analysis uncovers substantial regional variations in IFR2, from a low of 0.191 – 0.205% in the South to a high of 0.477% in the North. These differences are plausibly created by socio-economic factors (like differences in quality of governance and healthcare) rather than biological ones and provide policymakers the information necessary for welfare arbitrage and efficient resource allocation.

In closing, premature mortality is not only an indicator of health but also of economic cost and productivity, as discussed above and as has been evidenced for other health conditions in India (91). Furthermore, unforeseen death within a family or community may disturb the livelihood and income generation structure, thereby pervading to the broader welfare of impacted individuals, although reverse causation is present (92). Aside from the health lens, premature mortality and infectious disease mortality’s consequences for economic stability and ensuing welfare policy further support the need for continued attention to assessing the mortality burden of COVID-19 within India.

Data Availability

Data files and code used to produce the results herein are available on GitHub at the below repository.

https://github.com/lzimmermann4/india_c19_ifrs

Funding

The research was sponsored by funding from the University of Michigan School of Public Health and Center for Precision Health Data Science.

Author Contributions

Conceptualization: LZ, BM

Methodology: LZ, BM

Investigation: LZ, SB, SP, RK, RB, PG, BM

Supervision: BM

Writing – original draft: LZ, BM

Writing – review & editing: LZ, SB, SP, RK, RB, PG, BM

Competing interests

Authors have no competing interests

Acknowledgments

The authors thank the librarians from the University of Michigan Taubman Health Sciences Library for their instruction on developing the search strategy for this rapid review.

Supplementary Appendices

Appendix A. PRISMA checklist [1]

View this table:
  • View inline
  • View popup

Appendix B. Systematic review search procedure

To conduct the present systematic review, we systematically collected publications and preprints concerning infection fatality rates (IFRs) from SARS-CoV-2 in India and neighboring countries of Bangladesh, Nepal, Pakistan, and Sri Lanka. To identify relevant papers, we searched four databases: PubMed, Embase, Global Index Medicus, and isearch for preprints (encompassing bioRxiv, medRxiv, and SSRN). The search was conducted on July 3, 2021 and, as such, the results reflect published studies and preprints available from January 1, 2020 to July 3, 2021. Results were further verified through August 15, 2021 through reviewing media reports, government press releases, and manual search of preprints and publications. Data were extracted from the online search engines into the reference manager Zotero, deduplicated, and imported into Excel for screening.

The title/abstract screening, the full-text screening, and data abstraction were independently performed by two screeners to verify which studies met inclusion and exclusion criteria and to very data collected. When the two screeners disagreed on the marking for a citation, the screeners reached a consensus on whether to advance the citation to the next level of screening. Below we publish the full search strategies for each database.

PubMed (National Library of Medicine)

Date searched: 7/3/2021

Number of results: 2,940

Date filter: January 1, 2020 to [blank]

Other filters applied: None

1.

covid-19[tw] OR COVID19[tw] OR SARS-CoV-2[tw] OR SARS-CoV2[tw] OR severe acute respiratory syndrome coronavirus 2[tw] OR 2019-nCoV[tw] OR 2019nCoV[tw] OR coronavirus[tw] OR coronavirus[mh] OR covid-19[mh]

2.

india[text word] OR india[mesh] OR indian[text word] OR pakistan[text word] OR pakistani[text word] OR pakistan[mesh] OR bangladesh[text word] OR bangladeshi[text word] OR bangladesh[mesh] OR nepal[text word] OR nepal[mesh] OR “sri lanka”[text word] OR “sri lankan”[text word] OR “sri lanka”[mesh]

3.

IFR[text word] OR infection*[text word] OR CFR[text word] OR case*[text word] OR transmission*[text word] OR mortalit*[text word] OR mortality[mesh] OR fatalit*[text word] OR lethalit*[text word] OR death*[text word] OR burden[text word] OR underreporting[text word] OR “under-reporting”[text word] OR seroprevalence[text word] OR serosurvey[text word] OR serology[text word] OR serology[mesh] OR seroconversion[text word] OR seroconversion[mesh] OR “serosurveillance”[text word] OR Seroepidemiologic studies[mesh] OR seroepid*[text word] OR seropositiv*[text word] OR antibod*[text word] OR

antibodies[mesh] OR surveillance[text word] OR SIR[text word] OR SEIR[text word] OR “susceptible-exposed-infected-removed”[text word] OR “susceptible-infected-removed”[text word]

(1 AND 2 AND 3)

Embase (Elsevier)

Date searched: 7/3/2021

Number of results: 1,119

Date filter: 2020 to 2021

Other filters applied: Embase only and not Medline (as Medline is included in PubMed)

1.

covid-19:ti,ab,kw OR COVID19:ti,ab,kw OR SARS-CoV-2:ti,ab,kw OR SARS-CoV2:ti,ab,kw OR “severe acute respiratory syndrome coronavirus 2”:ti,ab,kw OR 2019-nCoV:ti,ab,kw OR 2019nCoV:ti,ab,kw OR coronavirus:ti,ab,kw OR ‘Coronavirinae’/exp OR ‘coronavirus disease 2019’/exp

2.

india:ti,ab,kw OR ‘india’/exp OR indian:ti,ab,kw OR pakistan:ti,ab,kw OR pakistani:ti,ab,kw OR ‘pakistan’/exp OR bangladesh:ti,ab,kw OR bangladeshi:ti,ab,kw OR ‘bangladesh’/de OR nepal:ti,ab,kw OR ‘nepal’/de OR “sri lanka”:ti,ab,kw OR “sri lankan”:ti,ab,kw OR ‘sri lanka’/de

3.

IFR:ti,ab,kw OR infection*:ti,ab,kw OR CFR:ti,ab,kw OR case*:ti,ab,kw OR transmission*:ti,ab,kw OR mortalit*:ti,ab,kw OR ‘mortality’/exp OR fatalit*:ti,ab,kw OR lethalit*:ti,ab,kw OR death*:ti,ab,kw OR burden:ti,ab,kw OR underreporting:ti,ab,kw OR under-reporting:ti,ab,kw OR seroprevalence:ti,ab,kw OR serosurv*:ti,ab,kw OR serology:ti,ab,kw OR ‘serology’/exp OR seroconversion:ti,ab,kw OR ‘seroconversion’/de OR ‘Seroepidemiology’/exp OR seroepid*:ti,ab,kw OR seropositiv*:ti,ab,kw OR antibod*:ti,ab,kw OR ‘antibody’/exp OR surveillance:ti,ab,kw OR SIR:ti,ab,kw OR SEIR:ti,ab,kw OR susceptible-exposed-infected-removed:ti,ab,kw OR susceptible-infected-removed:ti,ab,kw

(1 AND 2 AND 3)

isearch (National Library of Medicine)

Date searched: 7/3/2021

Number of results: 1,078

Date filter: January 1, 2020 to [blank]

Other filters applied: filtered to facets bioRxiv, medRxiv, SSRN; searched through title and abstract.

Note: Since isearch is curated to include COVID-19 related studies only, we translated the PubMed concept blocks 2 and 3.

(india OR indian OR pakistan OR pakistani OR bangladesh OR bangladeshi OR nepal OR “sri lanka” OR “sri lankan”) AND (IFR OR infection* OR CFR OR case* OR transmission* OR mortalit* OR fatalit* OR lethalit* OR death* OR burden OR underreporting OR “under-reporting” OR seroprevalence OR serosurvey OR serology OR seroconversion OR “serosurveillance” OR seroepid* OR seropositiv* OR antibod* OR surveillance OR SIR OR SEIR OR “susceptible-exposed-infected-removed” OR “susceptible-infected-removed”)

Global Index Medicus--SEAR & EMR (World Health Organization)

Note: We searched in IMSEAR (Index Medicus for the South-East Asia Region) for India, Bangladesh, Nepal, and Sri Lanka, and we searched in IMEMR (Index Medicus for the Eastern Mediterranean Region) for Pakistan.

For IMSEAR:

Date searched: 7/3/2021

Number of results: 35

Date filter: 2020 to [blank]

Other filters applied: Index filtered to “IMSEAR (South-East Asia)”; searched through title, abstract, subject.

(tw:(covid-19) OR tw:(COVID19) OR tw:(SARS-CoV-2) OR tw:(SARS-CoV2) OR tw:(“severe acute respiratory syndrome coronavirus 2”) OR tw:(2019-nCoV) OR tw:(2019nCoV) OR tw:(coronavirus)) AND (tw:(india) OR tw:(indian) OR tw:(bangladesh) OR tw:(bangladeshi) OR tw:(nepal) OR tw:(“sri lanka”) OR tw:(“sri lankan”)) AND (tw:(IFR) OR tw:(infection*) OR tw:(CFR) OR tw:(case*) OR tw:(transmission*) OR tw:(mortalit*) OR tw:(fatalit*) OR tw:(lethalit*) OR tw:(death*) OR tw:(burden) OR tw:(underreporting) OR tw:(“under-reporting”) OR tw:(seroprevalence) OR tw:(serosurvey) OR tw:(serology) OR tw:(seroconversion) OR tw:(“serosurveillance”) OR tw:(seroepid*) OR tw:(seropositiv*) OR tw:(antibod*) OR tw:(surveillance) OR tw:(SIR) OR tw:(SEIR) OR tw:(“susceptible-exposed-infected-removed”) OR tw:(“susceptible-infected-removed”))

For IMEMR:

Date searched: 7/3/2021

Number of results: 2

Date filter: 2020 to [blank]

Other filters applied: Index filtered to “IMEMR (Eastern Mediterranean)”; searched through title, abstract, subject.

(tw:(covid-19) OR tw:(COVID19) OR tw:(SARS-CoV-2) OR tw:(SARS-CoV2) OR tw:(“severe acute respiratory syndrome coronavirus 2”) OR tw:(2019-nCoV) OR tw:(2019nCoV) OR tw:(coronavirus)) AND (tw:(pakistan) OR tw:(pakistani)) AND (tw:(IFR) OR tw:(infection*) OR tw:(CFR) OR tw:(case*) OR tw:(transmission*) OR tw:(mortalit*) OR tw:(fatalit*) OR tw:(lethalit*) OR tw:(death*) OR tw:(burden) OR tw:(underreporting) OR tw:(“under-reporting”) OR tw:(seroprevalence) OR tw:(serosurvey) OR tw:(serology) OR tw:(seroconversion) OR tw:(“serosurveillance”) OR tw:(seroepid*) OR tw:(seropositiv*) OR tw:(antibod*) OR tw:(surveillance) OR tw:(SIR) OR tw:(SEIR) OR tw:(“susceptible-exposed-infected-removed”) OR tw:(“susceptible-infected-removed”))

Appendix C. Summary of included articles

View this table:
  • View inline
  • View popup
Table 1.

Summary of data abstraction from included studies.

Appendix D. List of excluded articles

View this table:
  • View inline
  • View popup
Table 1.

List of excluded articles from qualitative review and reason for exclusion.

Appendix E. Summary of excluded articles

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Summary of excluded articles by country, type of study, and reason

Appendix F. Meta-analysis methodology

The aims of the meta-analysis are two-fold (1) estimate a nationwide IFR1 and IFR2 with lower and upper bounds based on nationwide excess deaths, and (2) estimate regional IFR1 and IFR2 with lower and upper bounds based on state/city/district-specific excess deaths.

Data collection and preparation

A description of the data collection and preparation of the datafile for the meta-analysis is provided in the Methods section. Here we elaborate on aspects that require further explanation and clarification.

For included studies with a pre-calculated infection fatality rate, the IFR1 and/or IFR2, along with the 95% confidence interval, are directly extracted from the included study. For studies that provide a pre-calculated IFR1 but no IFR2 (i.e., do not further account for death underreporting), we compute the IFR2 through multiplying the numerator of the pre-calculated IFR1 by the appropriate range of excess deaths estimates. For studies that report a pre-calculated IFR2 but no IFR1 (i.e., do not provide preliminary infection fatality estimate without accounting for death reporting), we compute the IFR1, using the seroprevalence estimate quoted within the included study and following the same steps described below to compute IFR1.

For studies without a pre-calculated IFR1 and/or IFR2, IFR1 and/or IFR2 is computed, as given in the below formulas

Embedded Image Embedded Image

Where

Embedded Image

and

Embedded Image

For the denominator in formulas (a) and (b), the seroprevalence estimate corresponding to the general study population, as well as the 95% confidence interval, are directly extracted from the included study. We retrieved seroprevalence estimates that were adjusted (within the serosurvey design) for the test performance and weighted to be representative of the study’s general population (typically, for the demographics age and sex, among others, such as rural versus urban), if available. For studies that did not both weight and account for test performance, we extracted the solely weighted or solely test performance adjusted seroprevalence estimate, as provided. For studies that did not report either a weighted or a test performance adjusted seroprevalence estimate, we retrieved the provided crude seroprevalence estimates. The age-adjusted population estimate is calculated as the 2019 projected population estimate on the 2011 census website multiplied by the proportion of the population above the age-cutoff of the included study (e.g., proportion of the population of Karnataka aged ≥ 18 years), as obtained from the age composition for the study area from the 2011 census. As noted in the Results section, for select cities and districts, no 2019 projected population estimate was available and as such we use the 2011 census population estimates for the following cities and districts: Ahmedabad, Chennai, Bangalore Rural District, Indore, Ujjain. We note that this may lead to an overestimation of IFR1 nor IFR2 from these studies, and in turn slightly inflated pooled estimates for the regions containing these study locations.

For the numerator in formulas (a) and (b), COVID-19 reported cumulative deaths are sourced from covid19india.org and collected 14 days after the study end date to account for delay in death from SARS-CoV-2 symptom onset. In practice, reported (i.e., observed) deaths for the target population are obtained some specified number of days after the end date of the serological study that varies between studies (e.g., from 2 days [35] to 21 days [14] [18], among others). Levin et al., 2021 [148] perform a simulation-based sensitivity analysis to derive an appropriate fatality delay, and propose and adopt in their systematic review of age-specific infection fatality rates a fatality delay of 4 weeks after the midpoint of the serosurvey. As previously discussed, reported deaths were not available for select cities or districts in covid19india.org and so we were not able to compute IFR1 nor IFR2 for the cities or districts-level studies Berhampur, Bhubaneswar, Pimpri-Chinchiwad, Rourkela and Devarajeevana Halli slum in Bengaluru, and thereby were not able to include these studies in the quantitative meta-analysis (as listed in Appendix G).

For the numerator in formula (b), the death under reporting factor is either directly extracted from media reports and excess deaths studies available at the time of this report (as are listed in the Methods section) or calculated using excess cumulative deaths estimates provided within these sources. For the latter, URF (D) is computed as the provided excess deaths estimate divided by the COVID-19 reported deaths 14 days after the end date of the study end date, as previously reasoned. As previously noted, excess deaths were not available for the following states at the time of this study and so we were unable to compute IFR2, as well as include in the regional analysis, the following states and corresponding studies: Jammu and Kashmir (ref) and Puducherry (ref).

Being that the infection fatality rate (IFR) measure is understood to be a rate and that upon inspection its distribution was heavily right skewed, a log transformation is applied to the sampling data to approximate a normal distribution.

For the 95% confidence interval for IFR1, first we obtain the standard error for seroprevalence from the directly provided 95% confidence interval from each included study as

Embedded Image

Now that we have the standard error for seroprevalence, the standard error for the log of IFR1 can be obtained as IFR1 relies on Seroprevalence as detailed in formula (a) above. First, notice that

Embedded Image

By rules of logarithmic operations, it follows that

Embedded Image

By the definition in formula (a) and assuming Reported Deaths do not contribute to variability and are thereby fixed, it follows that

Embedded Image

where n is the study sample size and Embedded Image is the seroprevalence estimate from the included study.

By rules of logarithmic operations, we have that

Embedded Image

Assuming n does not contribute to variability and fixing at some constant

Embedded Image

Therefore, Embedded Image. Let us consider the variance of log (IFR1).

Substituting in for log (IFR1) from above, we have

Embedded Image

From the Taylor Series expansion, it follows that

Embedded Image

Then, the standard error for the log of IFR1 is given by

Embedded Image

where sesero is defined as in formula (c) above and Embedded Image is the directly provided seroprevalence estimate.

Then, letting Embedded Image denote the estimate of log (IFR1), the asymptotic approximate 95% confidence interval for log (IFR1) is as follows:

Embedded Image

The resulting confidence intervals are then exponentiated to back-transform from the logarithmic scale.

For the 95% confidence interval for IFR2, as the upper and lower bounds of the 95% confidence interval for the associated URF (D) are often not available (i.e., the range of uncertainty associated with excess deaths estimates is not consistently available), the asymptotic approximate 95% confidence interval for IFR2 is obtained by multiplying the 95% confidence interval for IFR1 by the associated URF (D).

Meta-analysis framework

A random effects model is used with the DerSimonian-Laird (DL) estimator for τ2 (also denoted as tau2), the variance of the true effect sizes. The DL estimator, Embedded Image is given by

Embedded Image

where QW denotes the appropriate test statistic with k-1 denoting the degrees of freedom and wi denotes the sampling weight for the Ctℎ included study datapoint.

The inverse variance approach is then used to obtain the pooled estimates (nationwide, regional, and state-specific within India). This means that the weighting in the random effects model is the inverse of the sampling variance, as follows

Embedded Image

where i denotes the itℎ included study datapoint, Embedded Image is the standard error from the itℎ included study estimate, and Embedded Image is the DL estimated random effects variance component, as defined in (e) above.

Using a random effects model with inverse variance method and DL estimator, the estimate for the pooled effect size is then given as follows:

Embedded Image

As previously mentioned, a log transformation is applied to the sampling data to approximate a normal distribution. In other words, we log transform both IFR1 and IFR2 in the meta-analysis and appropriately back-transform the resulting point estimates and standard errors by exponentiating the log-transformed values. Hence, Embedded Image in (e) above in this context is Embedded Image and, similarly, Embedded Image.

Then, to estimate the nationwide pooled infection fatality rates (IFR1 and IFR2) for India, countrywide IFR estimates (pre-calculated or computed) among included studies (as verified through August 15, 2021) are pooled, as provided in (e) above using the random effects framework detailed. The nationwide pooled infection fatality estimate includes the computed IFRs from each of the four nationwide seroprevalence surveys conducted consecutively for India, as stratifying by time periods (i.e., the nationwide first and second waves of SARS-CoV-2 in India) is of particular interest.

To estimate the regional pooled infection fatality rates (IFR1 and IFR2) in India, IFR estimates (pre-calculated or computed) from included studies within a state are pooled, as provided in (e) above with the same random effects approach outlined. Then, the regional IFR is estimated as the pooled IFR across pooled state level IFRs, as provided in (e) except where i now denotes the itℎ state. Since the regional analysis does not involve stratifying by waves (and thereby time points), for serial (or repeated) serosurveys for which multiple seroprevalence estimates are provided for a given study location at various time points, the most recent estimate is considered and included in the regional analysis.

Using the meta package in R, pooled effect sizes are estimated, as well as 95% confidence intervals, following the methodological framework above.

Appendix G. Summary of excluded articles from quantitative summary

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Summary of excluded articles from quantitative summary and reason for exclusion.

Appendix H. Summary of seroprevalence estimates within India

Below is a forest plot with the seroprevalence estimates used to compute IFR1 and in turn IFR2 (except for studies for which IFR2 was pre-calculated) in the meta-analysis of nationwide and regional IFRs.

Figure 1.
  • Download figure
  • Open in new tab
Figure 1.

Forest plot of SARS-CoV-2 seroprevalence estimates for India utilized in meta-analysis of IFR1 and IFR2.

Appendix I. Risk of bias assessment across included articles

See supplementary file Supplementary_RiskofBias.xlsx for results from the risk of bias assessment among the included studies in the meta-analysis, using the Joanna Briggs Institute (JBI) tool. Responses to each question in the JBI approach, as well as the cumulative score and rank of risk of bias, are detailed for each of the 19 studies (i.e. 15 serosurvey studies and 4 other study designs).

Appendix J. Assessment of publication bias

To formally test for funnel plot asymmetry, the Egger’s test (i.e., linear regression) is performed with a resulting p-value of 0.0501. Seeing as the significance level of the funnel plot intercept in the Egger’s test nearly meets the benchmark of 0.05, we further conduct the Begg’s test (i.e., rank correlation test) and with a p-value<0.0001, conclude that the funnel plot is asymmetric. As discussed within the Results section, despite the results of these diagnostic tests, we do not suspect that publication bias is the driving factor behind the observed asymmetry. Firstly, this is because the bulk of the included studies are seroprevalence studies, which are inherently large studies with rigorous study designs, thereby tending toward high precision (i.e., low standard errors). Secondly, there may be heterogeneity in the true effect size between the included studies for reasons such as geographic variation that may be attributing to the largely horizontal dispersion of the standard errors in Figure 6 (the funnel plot) in the Results section, and funnel plots assume a single true effect size.

Appendix K. SEIR-fansy model framework

(Note: Explanation below is unchanged from Supplementary Materials in previous submission1.)

Introduction

Here we are using the SEIR-fansy model1,2 and software package3 which uses a compartmental model accounting for false negative rates and preferential diagnostic testing for SARS-CoV-2 infections. The SEIR-fansy model can be represented by the compartmental model in Figure S1.

1. Purkayastha S, Kundu R, Bhaduri R, Barker D, Kleinsasser M, Debashree R, Mukherjee B. Estimating the wave 1 and wave 2 infection fatality rates from SARS-CoV-2 in India. BMC Res Notes. 14, 262 (2021). doi:10.1186/s13104-021-05652-2.

2. Bhaduri R, Kundu R, Purkayastha S, Kleinsasser M, Beesley LJ, Mukherjee B. Extending the Susceptible-Exposed-Infected-Removed (SEIR) model to handle the high false negative rate and symptom-based administration of Covid-19 diagnostic tests: SEIR-fansy. medRxiv [Preprint]. 2020 Sep 25:2020.09.24.20200238. doi: 10.1101/2020.09.24.20200238. PMID: 32995829; PMCID: PMC7523173.

3. Ritwik Bhaduri, Ritoban Kundu, Soumik Purkayastha, Lauren Beesley and Bhramar Mukherjee (2020). SEIRfansy: Extended Susceptible-Exposed-Infected-Recovery Model. R package version 1.1.0. https://CRAN.R-project.org/package=SEIRfansy

Figure S1:
  • Download figure
  • Open in new tab
Figure S1:

Schematic diagram for the SEIR-fansy model with imperfect testing and misclassification.

Mathematical framework

The following differential equations summarize the transmission dynamics being modeled.

Embedded Image Embedded Image

Using the Next Generation Matrix Method (28), we have calculated the basic reproduction number

Embedded Image

where S0 = λ/μ = 1 since we have assumed that natural birth and death rates are equal within this short period of time. In this setting, both β and R are time-varying parameters which are estimated using the Metropolis-Hastings MCMC method. To estimate the parameters, we at first need to solve the differential equations, which is difficult to perform in this continuous-time setting. It is also worth noting that we do not require the values of the variables for each time point. Instead, we only need their values at discrete time steps, i.e., for each day. Thus, we approximate the above set of differential equations by a set of recurrence relations. For any compartment X, the instantaneous rate of change with respect to time t (given by Embedded Image) is approximated by the difference between the counts of that compartment on the (t + 1)tℎ day and the ttℎ day, that is X(t + 1) − X(t). Starting with an initial value for each of the compartments on the Day 1 and using the discrete-time recurrence relations, we can then obtain the solutions of interest. Some examples of these discrete-time recurrence relations are presented below.

Embedded Image

The rest of the differential equations can each be similarly approximated by a discrete-time recurrence relation.

Likelihood assumptions and estimation

We use Bayesian estimation techniques and Markov chain Monte Carlo (MCMC) methods (namely, Metropolis-Hastings method with Gaussian proposal distribution) for estimating the parameters. First, we approximated the above set of differential equations using a discrete time approximation using daily differences. So, after we started with an initial value for each of the compartments on the day 1, using the discrete time recurrence relations we can find the counts for each of the compartments on the next days. To proceed with the MCMC-based estimation, we specify the likelihood explicitly. We assume (conditional on the parameters) the number of new confirmed cases on day RR depend only on the number of exposed individuals on the previous day. Specifically, we use multinomial modeling to incorporate the data on recovered and deceased cases as well. The joint conditional distribution is

Embedded Image

A multinomial distribution-like structure is then defined,

Embedded Image

Note: the expected values of E(t − 1) and P(t − 1) are obtained by solving the discrete time differential equations as described earlier.

Prior assumptions and MCMC

For the parameter r, we assume a U(0,1) prior, while for β, we assume an improper non-informative flat prior with the set of positive real numbers as support. After specifying the likelihood and the prior distributions of the parameters, we draw samples from the posterior distribution of the parameters using the Metropolis-Hastings algorithm with a Gaussian proposal distribution. We run the algorithm for 200,000 iterations with a burn-in period of 100,000. Finally, the mean of the parameters in each of the iterations are obtained as the final estimates of β and r for the different time periods. To obtain confidence intervals of various estimates we predict the number of individuals in each compartment given a set of parameters which are drawn using MCMC. This is done for 100,000 iterations. Using these values, we obtain the 95% Bayesian Credible Intervals of the estimates (such as infection fatality rates and underreporting factors)

Estimation of parameters of interest

Our main parameters of interest here are Underreporting factors for cases and deaths and Infection Fatality rate. Underreporting factors (URF) for cases and deaths are defined as follows:

Embedded Image

Here, total cumulative cases refers to all Cumulative cases including both reported and unreported cases. Similarly total cumulative deaths includes both reported and unreported deaths. Since we are unable to observe unreported cases or deaths we estimate total cumulative cases and deaths as follows:

  1. Total Cumulative cases at time t = P(t)+U(t)+F(t)+RR(t)+RU(t)+DR(t)+DU(t)

  2. Total Cumulative deaths at time t = DR(t)+DU(t)

To estimate the true fatality rate of COVID-19, we calculate 2 different infection fatality rates IFR1 and IFR2 as defined in formulas (a) and (b) respectively, in Supplementary Appendix F.

We also calculate the Case fatality rate as defined in the Methods section.

Now Cumulative Deaths follows a Bin(Observerd cumulative cases, CFRtrue) distribution, with the estimate of CFRtrue given by CFR, making CFR is a binomial proportion. Let Embedded Image and n = Observerd cumulative cases. So the asymptotic approximate 95% confidence interval is given by

Embedded Image

The estimates of infection fatality rates and underreporting factors are based on Bayesian credible intervals constructed from the exact posterior draws, as described before.

Appendix L. Data source and model-based results

The data has been sourced from covid19india.org. We used daily case-recovery-death count data from April 1, 2020 to January 31, 2021 for wave 1 and from February 1, 2021 – June 30, 2021 for wave 2. The predicted number of reported and total cases and deaths for January 31, 2021 (wave 1) and June 30 (for wave 2 and waves 1 and 2 combined) are shown in Tables S1, S2, and S3 respectively.

The mean estimates and the 95% CrI’s of underreporting factors for cases and deaths on January 31, 2021 are shown in Figure S2. Relevant wave 2 values are presented in Figure S3.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table T1:

Summary of the different metrics for the states and the nation for wave 1, on 31st January 2021

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table T2:

Summary of the different metrics for the states and the nation for wave 2, on 30th June 2021

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table T3:

Summary of the different metrics for the states and the nation for waves 1 and 2 combined, on 30th June 2021

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table T4:

Parameter values and descriptions for the SEIR-fansy model.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table T5:

Comparison of 4th nationwide serosurvey to combined estimates across waves 1 and 2.

Supplementary Figure 2.
  • Download figure
  • Open in new tab
Supplementary Figure 2. Forest plot of wave 1 and wave 2 infection fatality rates (IFR) and case fatality ratios (CFR) for SARS-CoV-2 in various states in India, where IFR1 includes reported deaths and IFR2 further includes the estimate of unreported deaths.
Supplementary Figure 3:
  • Download figure
  • Open in new tab
Supplementary Figure 3: Estimated first and second wave underreporting factors for cases and deaths associated with SARS-CoV-2 for states in India.

Footnotes

  • ↵1 The paucity of data in poorer countries has prompted some economists to adopt the benefit transfer method (BMT) – VSL estimates from richer countries are taken off-the-shelf and linearly scaled down to produce an estimate for poorer countries using the per capita GDP ratio. As Majumder and Madheswaran (2018) (85) note, this is likely to generate a significant underestimate since available data suggest the income elasticity of the demand for safety is considerably less than one, i.e., the poor are willing to pay a much higher proportion of their incomes to increase the chance of staying alive, in similar spirit to Engel’s Law for food.

  • ↵2 Other estimates of VSL in India are as follows: INR 14 - 19 million (86), INR 6.4 - 15 million (87), INR 14.8 – 15.4 million (88), INR 10.28 million (89).

REFERENCES

  1. 1.↵
    E. Dong, H. Du, L. Gardner, An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 20, 533–534 (2020).
    OpenUrlCrossRefPubMed
  2. 2.↵
    J. Gettleman, S. Yasir, H. Kumar, S. Raj, A. Loke, As Covid-19 Devastates India, Deaths Go Undercounted. N. Y. Times (2021), (available at https://www.nytimes.com/2021/04/24/world/asia/india-coronavirus-deaths.html).
  3. 3.↵
    A. Khalid, S. Ali, COVID-19 and its Challenges for the Healthcare System in Pakistan. Asian Bioeth. Rev. 12, 1–14 (2020).
    OpenUrlCrossRef
  4. 4.↵
    Nepal: “Struggling to breathe”: The second wave of Covid-19 in Nepal. Amnesty Int., (available at https://www.amnesty.org/en/wp-content/uploads/2021/07/ASA3142292021ENGLISH.pdf).
  5. 5.↵
    L. V. Zimmermann, M. Salvatore, G. R. Babu, B. Mukherjee, Estimating COVID-19‒ Related Mortality in India: An Epidemiological Challenge With Insufficient Data. Am. J. Public Health. 111, S59–S62 (2021).
    OpenUrl
  6. 6.↵
    A. Pan, L. Liu, C. Wang, H. Guo, X. Hao, Q. Wang, J. Huang, N. He, H. Yu, X. Lin, S. Wei, T. Wu, Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. JAMA. 323, 1915–1923 (2020).
    OpenUrlPubMed
  7. 7.↵
    A. Karlinsky, D. Kobak, Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset. eLife. 10, e69336 (2021).
    OpenUrl
  8. 8.↵
    SCORE Dashboard, (available at https://www.who.int/data/data-collection-tools/score/dashboard).
  9. 9.↵
    The true death toll of COVID-19: estimating global excess mortality, (available at https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess-mortality).
  10. 10.↵
    Excess Deaths Associated with COVID-19 (2021), (available at https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm).
  11. 11.↵
    S. Purkayastha, R. Bhattacharyya, R. Bhaduri, R. Kundu, X. Gu, M. Salvatore, D. Ray, S. Mishra, B. Mukherjee, A comparison of five epidemiological models for transmission of SARS-CoV-2 in India. BMC Infect. Dis. 21, 533 (2021).
    OpenUrlCrossRef
  12. 12.↵
    H. Campbell, P. Gustafson, medRxiv, in press, doi:10.1101/2021.05.12.21256975.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    S. Purkayastha, R. Kundu, R. Bhaduri, D. Barker, M. Kleinsasser, D. Ray, B. Mukherjee, Estimating the wave 1 and wave 2 infection fatality rates from SARS-CoV-2 in India. BMC Res. Notes. 14, 262 (2021).
  14. 14.↵
    G. Meyerowitz-Katz, L. Merone, A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates. Int. J. Infect. Dis. 101, 138–148 (2020).
    OpenUrlPubMed
  15. 15.↵
    A. T. Levin, W. P. Hanage, N. Owusu-Boaitey, K. B. Cochran, S. P. Walsh, G. Meyerowitz-Katz, Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur. J. Epidemiol. 35, 1123–1138 (2020).
    OpenUrlPubMed
  16. 16.↵
    A. Rostami, M. Sepidarkish, M. M. G. Leeflang, S. M. Riahi, M. Nourollahpour Shiadeh, S. Esfandyari, A. H. Mokdad, P. J. Hotez, R. B. Gasser, SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 27, 331–340 (2021).
    OpenUrl
  17. 17.↵
    World Population Prospects - Population Division - United Nations, (available at https://population.un.org/wpp/).
  18. 18.↵
    L. J. Carter, L. V. Garner, J. W. Smoot, Y. Li, Q. Zhou, C. J. Saveson, J. M. Sasso, A. C. Gregg, D. J. Soares, T. R. Beskid, S. R. Jervey, C. Liu, Assay Techniques and Test Development for COVID-19 Diagnosis. ACS Cent. Sci. 6, 591–605 (2020).
    OpenUrl
  19. 19.↵
    D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, T. P. Group, Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLOS Med. 6, e1000097 (2009).
    OpenUrlCrossRefPubMed
  20. 20.↵
    Coronavirus in India: Latest Map and Case Count, (available at https://www.covid19india.org).
  21. 21.↵
    C. T. Leffler, J. D. L. V. E. Yang, “Preliminary Analysis of Excess Mortality in India During the Covid-19 Pandemic (Update August 4, 2021)” (2021), p. 2021.08.04.21261604, doi:10.1101/2021.08.04.21261604.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    Y. Deshmukh, W. Suraweera, C. Tumbe, A. Bhowmick, S. Sharma, P. Novosad, S. H. Fu, L. Newcombe, H. Gelband, P. Brown, P. Jha, medRxiv, in press, doi:10.1101/2021.07.20.21260872.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    Three New Estimates of India’s All-Cause Excess Mortality during the COVID-19 Pandemic. Cent. Glob. Dev., (available at https://cgdev.org/publication/three-new-estimates-indias-all-cause-excess-mortality-during-covid-19-pandemic).
  24. 24.↵
    R. S, Interpreting deaths in Chennai. The Hindu (2021), (available at https://www.thehindu.com/opinion/op-ed/interpreting-deaths-in-chennai/article34645264.ece).
  25. 25.↵
    VitalStatisticsReport - MyBMC - Welcome to BMC’s Website, (available at https://portal.mcgm.gov.in/irj/portal/anonymous/qlvitalstatsreport?guest_user=english).
  26. 26.↵
    Mumbai Had 13k “Excess” Deaths in March-July. How Does Its COVID Story Change? - The Wire Science, (available at https://science.thewire.in/the-sciences/covid-19-mumbai-all-cause-mortality-data-ifr-bmc-seroprevalence-survey/).
  27. 27.↵
    I. T. B. B. Delhi/G, hinagar June 23, 2021UPDATED: June 23, 2021 22:10 Ist, Excess deaths challenge India’s official Covid toll. India Today, (available at https://www.indiatoday.in/coronavirus-outbreak/story/excess-deaths-challenge-india-s-official-covid-toll-1818564-2021-06-23).
  28. 28.↵
    S. Ramani, Excess deaths in Maharashtra were at least 3 times the official COVID toll. The Hindu (2021), (available at https://www.thehindu.com/news/national/excess-deaths-in-maharashtra-were-at-least-3-times-the-official-covid-toll/article35708965.ece).
  29. 29.↵
    S. S. Srivatsa, S. Ramani, Karnataka’s excess deaths nearly 6 times official COVID-19 toll. The Hindu (2021), (available at https://www.thehindu.com/news/national/excess-deaths-in-karnataka-nearly-six-times-official-covid-19-tally/article34870624.ece).
  30. 30.↵
    S. Ramachandran, A. Malani, medRxiv, in press, doi:10.1101/2021.07.20.21260577.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    Development Data Lab, (available at https://www.devdatalab.org/covid).
  32. 32.↵
    C. Z. Guilmoto, “Estimating the death toll of the Covid-19 pandemic in India” (2021), p. 2021.06.29.21257965, doi:10.1101/2021.06.29.21257965.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    S. Balduzzi, G. Rücker, G. Schwarzer, How to perform a meta-analysis with R: a practical tutorial. Evid. Based Ment. Health. 22, 153–160 (2019).
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    W. Viechtbauer, Conducting Meta-Analyses in R with the metafor Package. J. Stat. Softw. 36, 1–48 (2010).
    OpenUrlCrossRefPubMed
  35. 35.↵
    Population, total - India | Data, (available at https://data.worldbank.org/indicator/SP.POP.TOTL?locations=IN).
  36. 36.↵
    Census 2011 India, (available at https://www.census2011.co.in/).
  37. 37.↵
    Census of India: Age Structure And Marital Status, (available at https://censusindia.gov.in/census_and_you/age_structure_and_marital_status.aspx).
  38. 38.↵
    Cochrane Handbook for Systematic Reviews of Interventions, (available at https://training.cochrane.org/handbook).
  39. 39.↵
    Z. Munn, S. Moola, K. Lisy, D. Riitano, C. Tufanaru, Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. JBI Evid. Implement. 13, 147–153 (2015).
    OpenUrl
  40. 40.↵
    S. Moola, Z. Munn, C. Tufanaru, E. Aromataris, K. Sears, R. Sfetc, M. Currie, K. Lisy, R. Qureshi, P. Mattis, P.-F. Mu, in JBI Manual for Evidence Synthesis, E. Aromataris, Z. Munn, Eds. (JBI, 2020; https://wiki.jbi.global/display/MANUAL/Chapter+7%3A+Systematic+reviews+of+etiology+and+risk).
  41. 41.
    M. J. Page, J. E. McKenzie, P. M. Bossuyt, I. Boutron, T. C. Hoffmann, C. D. Mulrow, L. Shamseer, J. M. Tetzlaff, E. A. Akl, S. E. Brennan, R. Chou, J. Glanville, J. M. Grimshaw, A. Hróbjartsson, M. M. Lalu, T. Li, E. W. Loder, E. Mayo-Wilson, S. McDonald, L. A. McGuinness, L. A. Stewart, J. Thomas, A. C. Tricco, V. A. Welch, P. Whiting, D. Moher, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst. Rev. 10, 89 (2021).
    OpenUrlCrossRefPubMed
  42. 42.↵
    O. Prakash, B. Solanki, J. K. Sheth, M. Kadam, S. Vyas, Severe acute respiratory syndrome coronavirus 2 immunoglobulin G antibody: Seroprevalence among contacts of COVID-19 cases. Indian J. Public Health. 65, 5–10 (2021).
    OpenUrlCrossRef
  43. 43.↵
    L. R. Inbaraj, C. E. George, S. Chandrasingh, Seroprevalence of COVID-19 infection in a rural district of South India: A population-based seroepidemiological study. PloS One. 16, e0249247 (2021).
    OpenUrlCrossRef
  44. 44.↵
    J. S. Kshatri, D. Bhattacharya, S. Kanungo, S. Giri, S. K. Palo, D. Parai, J. Turuk, A. Mansingh, H. R. Choudhary, M. Pattnaik, G. C. Dash, P. Mohanty, N. Mishra, D. M. Satapathy, S. K. Sahoo, S. Pati, Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India. Sci. Rep. 11, 10551 (2021).
    OpenUrlCrossRef
  45. 45.↵
    J. S. Kshatri, D. Bhattacharya, I. Praharaj, A. Mansingh, D. Parai, S. Kanungo, S. K. Palo, S. Giri, M. Pattnaik, S. R. Barik, G. C. Dash, H. R. Choudhary, J. Turuk, N. N. Mandal, S. Pati, Seroprevalence of SARS-CoV-2 in Bhubaneswar, India: findings from three rounds of community surveys. Epidemiol. Infect. 149, e139 (2021).
    OpenUrl
  46. 46.↵
    S. Selvaraju, M. S. Kumar, J. W. V. Thangaraj, T. Bhatnagar, V. Saravanakumar, C. P. G. Kumar, K. Sekar, E. Ilayaperumal, R. Sabarinathan, M. Jagadeesan, M. S. Hemalatha, M. V. Murhekar, Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India. Emerg. Infect. Dis. 27, 586–589 (2021).
    OpenUrl
  47. 47.↵
    A look at serological surveys conducted in Delhi. Hindustan Times (2021), (available at https://www.hindustantimes.com/cities/delhi-news/a-look-at-serological-surveys-conducted-in-delhi-101612270983224.html).
  48. 48.↵
    N. Sharma, P. Sharma, S. Basu, S. Saxena, R. Chawla, K. Dushyant, N. Mundeja, Z. S. Marak, S. Singh, G. K. Singh, R. Rustagi, medRxiv, in press, doi:10.1101/2020.12.13.20248123.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    N. M. Babu, Percentage of people with antibodies high, shows Delhi serological survey. The Hindu (2020), (available at https://www.thehindu.com/news/cities/Delhi/percentage-of-people-with-antibodies-high/article32156162.ece).
  50. 50.↵
    P. Misra, S. Kant, R. Guleria, S. K. Rai, W. U. S. study team of Aiims, medRxiv, in press, doi:10.1101/2021.06.15.21258880.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    C. E. George, L. R. Inbaraj, S. Chandrasingh, L. P. de Witte, High seroprevalence of COVID-19 infection in a large slum in South India; what does it tell us about managing a pandemic and beyond? Epidemiol. Infect. 149, e39 (2021).
    OpenUrlCrossRef
  52. 52.↵
    M. Mohanan, A. Malani, K. Krishnan, A. Acharya, medRxiv, in press, doi:10.1101/2020.11.02.20224782.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    G. R. Babu, R. Sundaresan, S. Athreya, J. Akhtar, P. K. Pandey, P. S. Maroor, M. R. Padma, R. Lalitha, M. Shariff, L. Krishnappa, C. N. Manjunath, M. K. Sudarshan, G. Gururaj, T. S. Ranganath, K. D. E. Vasanth, P. Banandur, D. Ravi, S. Shiju, E. Lobo, A. Satapathy, L. Alahari, P. Dinesh, V. Thakar, A. Desai, A. Rangaiah, A. Munivenkatappa, K. S. S. G. Basawarajappa, H. G. Sreedhara, S. Kc, A. K. B N. Umar, M. Ba, R. Vasanthapuram, The burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population: Results from a statewide sentinel-based population survey in Karnataka, India. Int. J. Infect. Dis. 108, 27–36 (2021).
    OpenUrlCrossRef
  54. 54.↵
    S. M. S. Khan, M. A. Qurieshi, I. Haq, S. Majid, J. Ahmad, T. Ayub, A. B. Fazili, A. A. Bhat, A. M. Ganai, Y. Jan, R.-R. Kaul, Z. A. Khan, M. A. Masoodi, B. Mushtaq, F. Nazir, M. Nazir, M. W. Raja, M. Rasool, A. Asma, M. Aziz, S. Ayoub, A. A. Bhat, I. N. Chowdri, S. Ismail, M. F. Kawoosa, M. A. Khan, M. S. Khan, R. Kousar, A. A. Lone, S. Nabi, M. Obaid, T. B. Qazi, I. Sabah, I. A. Sumji, “Results of a Population-Based Survey to Estimate the Seroprevalence of SARS-CoV-2 Specific IgG Antibodies in Kashmir, India, Seven Months after the Appearance of the First COVID-19 Case” (SSRN Scholarly Paper ID 3820632, Social Science Research Network, Rochester, NY, 2021), doi:10.2139/ssrn.3820632.
    OpenUrlCrossRef
  55. 55.↵
    S. Sakalle, S. Saroshe, H. Shukla, A. Mutha, A. Vaze, A. Arora, A. Athotra, S. Ramaswamy, A. Jain, M. Dhuria, A. D. Patil, A. Rai, S. Garg, S. K. Jain, J. Bindal, S. K. Singh, Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020. J. Fam. Med. Prim. Care. 10, 1479– 1484 (2021).
    OpenUrlCrossRef
  56. 56.↵
    Tata Institute of Fundamental Research, SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2, (available at https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf).
  57. 57.↵
    S. Reporter, Third sero survey: antibodies in 36.30% samples in Mumbai. The Hindu (2021), (available at https://www.thehindu.com/news/cities/mumbai/third-sero-survey-antibodies-in-3630-samples-in-mumbai/article34404107.ece).
  58. 58.↵
    A. Malani, D. Shah, G. Kang, G. N. Lobo, J. Shastri, M. Mohanan, R. Jain, S. Agrawal, S. Juneja, S. Imad, U. Kolthur-Seetharam, Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India. Lancet Glob. Health. 9, e110–e111 (2021).
    OpenUrl
  59. 59.↵
    PIB’S BULLETIN ON COVID-19, (available at https://pib.gov.in/pib.gov.in/Pressreleaseshare.aspx?PRID=1740000).
  60. 60.↵
    M. V. Murhekar, T. Bhatnagar, J. W. V. Thangaraj, V. Saravanakumar, M. S. Kumar, S. Selvaraju, K. Rade, C. P. G. Kumar, R. Sabarinathan, A. Turuk, S. Asthana, R. Balachandar, S. D. Bangar, A. K. Bansal, V. Chopra, D. Das, A. K. Deb, K. R. Devi, V. Dhikav, G. R. Dwivedi, S. M. S. Khan, M. S. Kumar, A. Laxmaiah, M. Madhukar, A. Mahapatra, C. Rangaraju, J. Turuk, R. Yadav, R. Andhalkar, K. Arunraj, D. K. Bharadwaj, P. Bharti, D. Bhattacharya, J. Bhat, A. S. Chahal, D. Chakraborty, A. Chaudhury, H. Deval, S. Dhatrak, R. Dayal, D. Elantamilan, P. Giridharan, I. Haq, R. K. Hudda, B. Jagjeevan, A. Kalliath, S. Kanungo, N. N. Krishnan, J. S. Kshatri, A. Kumar, N. Kumar, V. G. V. Kumar, G. G. J. N. Lakshmi, G. Mehta, N. K. Mishra, A. Mitra, K. Nagbhushanam, A. Nimmathota, A. R. Nirmala, A. K. Pandey, G. V. Prasad, M. A. Qurieshi, S. D. Reddy, A. Robinson, S. Sahay, R. Saxena, K. Sekar, V. K. Shukla, H. B. Singh, P. K. Singh, P. Singh, R. Singh, N. Srinivasan, D. S. Varma, A. Viramgami, V. C. Wilson, S. Yadav, S. Yadav, K. Zaman, A. Chakrabarti, A. Das, R. S. Dhaliwal, S. Dutta, R. Kant, A. M. Khan, K. Narain, S. Narasimhaiah, C. Padmapriyadarshini, K. Pandey, S. Pati, S. Patil, H. Rajkumar, T. Ramarao, Y. K. Sharma, S. Singh, S. Panda, D. C. S. Reddy, B. Bhargava, T. Anand, G. R. Babu, H. Chauhan, T. Dikid, R. R. Gangakhedkar, S. Kant, S. Kulkarni, J. P. Muliyil, R. M. Pandey, S. Sarkar, N. Shah, A. Shrivastava, S. K. Singh, S. Zodpe, A. Hindupur, P. R. Asish, M. Chellakumar, D. Chokkalingam, S. Dasgupta, M. M. E. Gowtham, A. Jose, K. Kalaiyarasi, N. N. Karthik, T. Karunakaran, G. Kiruthika, H. Dinesh Kumar, S. Sarath Kumar, M. P. Sarath Kumar, E. Michaelraj, J. Pradhan, E. B. Arun Prasath, D. Gladys Angelin Rachel, S. Rani, A. Rozario, R. Sivakumar, P. Gnana Soundari, K. Sujeetha, A. Vinod, SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020–January 2021. Int. J. Infect. Dis. 108, 145–155 (2021).
    OpenUrlCrossRefPubMed
  61. 61.↵
    M. V. Murhekar, T. Bhatnagar, S. Selvaraju, V. Saravanakumar, J. W. V. Thangaraj, N. Shah, M. S. Kumar, K. Rade, R. Sabarinathan, S. Asthana, R. Balachandar, S. D. Bangar, A. K. Bansal, J. Bhat, V. Chopra, D. Das, A. K. Deb, K. R. Devi, G. R. Dwivedi, S. M. S. Khan, C. P. G. Kumar, M. S. Kumar, A. Laxmaiah, M. Madhukar, A. Mahapatra, S. S. Mohanty, C. Rangaraju, A. Turuk, D. K. Baradwaj, A. S. Chahal, F. Debnath, I. Haq, A. Kalliath, S. Kanungo, J. S. Kshatri, G. G. J. N. Lakshmi, A. Mitra, A. R. Nirmala, G. V. Prasad, M. A. Qurieshi, S. Sahay, R. K. Sangwan, K. Sekar, V. K. Shukla, P. K. Singh, P. Singh, R. Singh, D. S. Varma, A. Viramgami, S. Panda, D. C. S. Reddy, B. Bhargava, R. Andhalkar, A. Chaudhury, H. Deval, S. Dhatrak, R. R. Gupta, E. Ilayaperumal, B. Jagjeevan, R. C. Jha, K. Kiran, N. N. Krishnan, A. Kumar, V. V. Kumar, K. Nagbhushanam, A. Nimmathota, A. K. Pandey, H. S. Pawar, K. S. Rathore, A. Robinson, H. B. Singh, V. C. Wilson, A. Yadav, R. Yadav, T. Karunakaran, J. Pradhan, T. Sivakumar, A. Jose, K. Kalaiyarasi, S. Dasgupta, R. Anusha, T. Anand, G. R. Babu, H. Chauhan, T. Dikid, R. R. Gangakhedkar, S. Kant, S. Kulkarni, J. P. Muliyil, R. M. Pandey, S. Sarkar, A. Shrivastava, S. K. Singh, S. Zodpey, A. Das, P. Das, S. Dutta, R. Kant, K. Narain, S. Narasimhaiah, S. Pati, S. Patil, H. Rajkumar, T. Ramarao, K. Sarkar, S. Singh, G. S. Toteja, K. Zaman, SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey. Lancet Glob. Health. 9, e257–e266 (2021).
    OpenUrl
  62. 62.↵
    M. V. Murhekar, T. Bhatnagar, S. Selvaraju, K. Rade, V. Saravanakumar, J. W. V. Thangaraj, M. S. Kumar, N. Shah, R. Sabarinathan, A. Turuk, P. K. Anand, S. Asthana, R. Balachandar, S. D. Bangar, A. K. Bansal, J. Bhat, D. Chakraborty, C. Rangaraju, V. Chopra, D. Das, A. K. Deb, K. R. Devi, G. R. Dwivedi, S. M. S. Khan, I. Haq, M. S. Kumar, A. Laxmaiah Madhuka, A. Mahapatra, A. Mitra, A. R. Nirmala, A. Pagdhune, M. A. Qurieshi, T. Ramarao, S. Sahay, Y. K. Sharma, M. B. Shrinivasa, V. K. Shukla, P. K. Singh, A. Viramgami, V. C. Wilson, R. Yadav, C. G. Kumar, H. E. Luke, U. D. Ranganathan, S. Babu, K. Sekar, P. D. Yadav, G. N. Sapkal, A. Das, P. Das, S. Dutta, R. Hemalatha, A. Kumar, K. Narain, S. Narasimhaiah, S. Panda, S. Pati, S. Patil, K. Sarkar, S. Singh, R. Kant, S. Tripathy, G. S. Toteja, G. R. Babu, S. Kant, J. P. Muliyil, R. M. Pandey, S. Sarkar, S. K. Singh, S. Zodpey, R. R. Gangakhedkar, D. S. Reddy, B. Bhargava, Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020. Indian J. Med. Res. 152, 48 (2020).
    OpenUrlPubMed
  63. 63.↵
    A. Banerjee, B. Gaikwad, A. Desale, S. L. Jadhav, J. Bhawalkar, P. Salve, V. Dange, C. Raut, H. Rathod, K. Srivastava, “SARS-CoV-2 Seroprevalence Study in Pimpri-Chinchwad, Maharashtra, India Coinciding with Falling Trend – Do the Results Suggest Imminent Herd Immunity?” (SSRN Scholarly Paper ID 3729394, Social Science Research Network, Rochester, NY, 2020), doi:10.2139/ssrn.3729394.
    OpenUrlCrossRef
  64. 64.↵
    S. S. Kar, S. Sarkar, S. Murali, R. Dhodapkar, N. M. Joseph, R. Aggarwal, Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August–October 2020. Emerg. Infect. Dis. 27, 666–669 (2021).
    OpenUrlCrossRef
  65. 65.↵
    A. Malani, S. Ramachandran, V. Tandel, R. Parasa, S. Imad, S. Sudharshini, V. Prakash, Y. Yogananth, S. Raju, T. S. Selvavinayagam, medRxiv, in press, doi:10.1101/2021.02.03.21250949.
    OpenUrlAbstract/FREE Full Text
  66. 66.↵
    A. Joshi, P. Shankar, A. Chatterjee, J. Singh, A. Pakhare, K. Yadav, A. Shrivas, A. K. Maurya, R. S. Nagi, D. Biswas, A. M. Kokane, S. Singh, Heterogeneous patterns of COVID-19 transmission in an Urban set up – sero-epidemiological survey data from Ujjain, Madhya Pradesh (a central Indian city). Data Brief. 37, 107169 (2021).
    OpenUrlCrossRef
  67. 67.↵
    M. I. Nisar, N. Ansari, F. Khalid, M. Amin, H. Shahbaz, A. Hotwani, N. Rehman, S. Pugh, U. Mehmood, A. Rizvi, A. Memon, Z. Ahmed, A. Ahmed, J. Iqbal, A. F. Saleem, U. B. Aamir, D. B. Larremore, B. Fosdick, F. Jehan, Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan. Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis. 106, 176–182 (2021).
    OpenUrlCrossRef
  68. 68.↵
    M. Haq, A. Rehman, J. Ahmad, U. Zafar, S. Ahmed, M. A. Khan, A. Naveed, H. Rajab, F. Muhammad, W. Naushad, M. Aman, H. U. Rehman, S. Ahmad, S. Anwar, N. U. Haq, SARS-CoV-2: big seroprevalence data from Pakistan-is herd immunity at hand? Infection, 1–6 (2021).
  69. 69.↵
    Estimates of COVID-19 infection fatality rate in Chennai - Mathematics, (available at https://maths.mdx.ac.uk/research/modelling-the-covid-19-pandemic/chennaiifrestimates/).
  70. 70.↵
    R. Bhattacharyya, R. Kundu, R. Bhaduri, D. Ray, L. J. Beesley, M. Salvatore, B. Mukherjee, Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates. Sci. Rep. 11, 9748 (2021).
    OpenUrlCrossRefPubMed
  71. 71.↵
    D. K. Hazra, B. S. Pujari, S. M. Shekatkar, F. Mozaffer, S. Sinha, V. Guttal, P. Chaudhuri, G. I. Menon, medRxiv, in press, doi:10.1101/2021.06.02.21258203.
    OpenUrlAbstract/FREE Full Text
  72. 72.↵
    R. Cai, P. Novosad, V. Tandel, S. Asher, A. Malani, Representative Estimates of COVID-19 Infection Fatality Rates from Three Locations in India. medRxiv (2021), doi:10.1101/2021.01.05.21249264.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    M. Banaji, medRxiv, in press, doi:10.1101/2021.04.08.21255101.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    G.-A.-U. G.- Öffentlichkeitsarbeit, COVID-19 - Georg-August-Universität Göttingen, (available at https://www.uni-goettingen.de/en/606540.html).
  75. 75.↵
    R. Bhaduri, R. Kundu, S. Purkayastha, M. Kleinsasser, L. J. Beesley, B. Mukherjee, medRxiv, in press, doi:10.1101/2020.09.24.20200238.
    OpenUrlAbstract/FREE Full Text
  76. 76.↵
    S. Goli, K. S. James, medRxiv, in press, doi:10.1101/2020.04.09.20059014.
    OpenUrlAbstract/FREE Full Text
  77. 77.
    Rukmini S, Madhya Pradesh saw nearly three times more deaths than normal after second wave of Covid-19 struck. Scroll.in, (available at https://scroll.in/article/996772/madhya-pradesh-saw-nearly-three-times-more-deaths-than-normal-after-second-wave-of-covid-19-struck).
  78. 78.
    61k Covid deaths not counted in Gujarat: Report. Hindustan Times (2021), (available at https://www.hindustantimes.com/india-news/61k-covid-deaths-not-counted-in-gujarat-report-101621027267608.html).
  79. 79.↵
    N. Wang, How to Conduct a Meta-Analysis of Proportions in R: A Comprehensive Tutorial (2018).
  80. 80.
    Population, total - Bangladesh, Nepal, Pakistan, Sri Lanka, India | Data, (available at https://data.worldbank.org/indicator/SP.POP.TOTL?locations=BD-NP-PK-LK-IN).
  81. 81.
    COVID Live Update: 213,646,658 Cases and 4,459,162 Deaths from the Coronavirus - Worldometer, (available at https://www.worldometers.info/coronavirus/).
  82. 82.↵
    H. Rahmandad, T. Y. Lim, J. Sterman, Behavioral dynamics of COVID-19: estimating underreporting, multiple waves, and adherence fatigue across 92 nations. Syst. Dyn. Rev. 37, 5–31 (2021).
    OpenUrl
  83. 83.↵
    The pandemic’s true deaths toll. The Economist (2021), (available at https://www.economist.com/graphic-detail/coronavirus-excess-deaths-estimates).
  84. 84.↵
    R. Thaler, S. Rosen, in Household Production and Consumption (NBER, 1976; https://www.nber.org/books-and-chapters/household-production-and-consumption/value-saving-life-evidence-labor-market), pp. 265–302.
  85. 85.↵
    A. Majumder, S. Madheswaran, Value of Statistical Life in India: A Hedonic Wage Approach, 24.
  86. 86.↵
    Shanmugam, K R., The Value of Life: Estimates from Indian Labour Market, (available at https://www.proquest.com/openview/ef7bca1b0c4a3687f5795066574b5919/1?pq-origsite=gscholar&cbl=1819379).
  87. 87.↵
    N. B. Simon, M. L. Cropper, A. Alberini, S. Arora, “Valuing mortality reductions in India : a study of compensating wage differentials,” Policy Research Working Paper Series (2078, The World Bank, 1999), (available at https://ideas.repec.org/p/wbk/wbrwps/2078.html).
  88. 88.↵
    by S. Madheswaran, “Measuring the value of life and limb: Estimating compensating wage differentials among workers in Chennai and Mumbai,” Working papers (27, The South Asian Network for Development and Environmental Economics), (available at https://ideas.repec.org/p/snd/wpaper/27.html).
  89. 89.↵
    K. Shanmugam, S. Madheswaran, in Environmental Valuation: In South Asia (2011), pp. 412–443.
  90. 90.
    National Accounts Data | MOSPI, (available at https://mospi.gov.in/web/mospi/download-tables-data/-/reports/view/templateOne/16701?q=TBDCAT).
  91. 91.↵
    A. Pearce, L. Sharp, P. Hanly, A. Barchuk, F. Bray, M. de Camargo Cancela, P. Gupta, F. Meheus, Y.-L. Qiao, F. Sitas, S.-M. Wang, I. Soerjomataram, Productivity losses due to premature mortality from cancer in Brazil, Russia, India, China, and South Africa (BRICS): A population-based comparison. Cancer Epidemiol. 53, 27–34 (2018).
    OpenUrlCrossRefPubMed
  92. 92.↵
    N. Saikia, F. Ram, Determinants of Adult Mortality in India. Asian Popul. Stud. 6, 153–171 (2010).
    OpenUrl

References

  1. [1].
    M. J. Page et al., “The PRISMA 2020 statement: an updated guideline for reporting systematic reviews,” Syst. Rev., vol. 10, no. 1, p. 89, Mar. 2021, doi: 10.1186/s13643-021-01626-4.
    OpenUrlCrossRefPubMed
  2. [2].
    O. Prakash et al., “Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study.,” BMJ Open, vol. 11, no. 1, p. e044101, Jan. 2021, doi: 10.1136/bmjopen-2020-044101.
    OpenUrlAbstract/FREE Full Text
  3. [3].
    L. R. Inbaraj, C. E. George, and S. Chandrasingh, “Seroprev4alence of COVID-19 infection in a rural district of South India: A population-based seroepidemiological study.,” PloS One, vol. 16, no. 3, p. e0249247, 2021, doi: 10.1371/journal.pone.0249247.
    OpenUrlCrossRef
  4. [4].
    J. S. Kshatri et al., “Seroprevalence of SARS-CoV-2 in Bhubaneswar, India: findings from three rounds of community surveys.,” Epidemiol. Infect., vol. 149, p. e139, Apr. 2021, doi: 10.1017/S0950268821000972.
    OpenUrlCrossRef
  5. [5].
    J. S. Kshatri et al., “Serological surveys to inform SARS-CoV-2 epidemic curve: a cross-sectional study from Odisha, India.,” Sci. Rep., vol. 11, no. 1, p. 10551, May 2021, doi: 10.1038/s41598-021-89877-y.
    OpenUrlCrossRef
  6. [6].
    S. Selvaraju et al., “Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India.,” Emerg. Infect. Dis., vol. 27, no. 2, pp. 586–589, Feb. 2021, doi: 10.3201/eid2702.203938.
    OpenUrlCrossRef
  7. [7].
    “Estimates of COVID-19 infection fatality rate in Chennai - Mathematics.” https://maths.mdx.ac.uk/research/modelling-the-covid-19-pandemic/chennaiifrestimates/ (accessed Aug. 14, 2021).
  8. [8].
    “A look at serological surveys conducted in Delhi,” Hindustan Times, Feb. 02, 2021. https://www.hindustantimes.com/cities/delhi-news/a-look-at-serological-surveys-conducted-in-delhi-101612270983224.html (accessed Aug. 09, 2021).
  9. [9].
    P. Sharma et al., “Seroprevalence of antibodies to SARS-CoV-2 and predictors of seropositivity among employees of a teaching hospital in New Delhi, India.,” Osong Public Health Res. Perspect., vol. 12, no. 2, pp. 88–95, Apr. 2021, doi: 10.24171/j.phrp.2021.12.2.06.
    OpenUrlCrossRef
  10. [10].
    N. M. Babu, “Percentage of people with antibodies high, shows Delhi serological survey,” The Hindu, New Delhi, Jul. 22, 2020. Accessed: Aug. 09, 2021. [Online]. Available: https://www.thehindu.com/news/cities/Delhi/percentage-of-people-with-antibodies-high/article32156162.ece
  11. [11].
    R. Bhattacharyya et al., “Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates.,” Sci. Rep., vol. 11, no. 1, p. 9748, May 2021, doi: 10.1038/s41598-021-89127-1.
    OpenUrlCrossRefPubMed
  12. [12].
    D. K. Hazra et al., “The INDSCI-SIM model for COVID-19 in India,” medRxiv, p. 2021.06.02.21258203, Jun. 2021, doi: 10.1101/2021.06.02.21258203.
    OpenUrlAbstract/FREE Full Text
  13. [13].
    P. Misra, S. Kant, R. Guleria, S. K. Rai, and W. U. S. study team of Aiims, “Serological prevalence of SARS-CoV-2 antibody among children and young age (between age 2-17 years) group in India: An interim result from a large multi-centric population-based seroepidemiological study,” medRxiv, p. 2021.06.15.21258880, Jun. 2021, doi: 10.1101/2021.06.15.21258880.
    OpenUrlAbstract/FREE Full Text
  14. [14].
    C. E. George, L. R. Inbaraj, S. Chandrasingh, and L. P. de Witte, “High seroprevalence of COVID-19 infection in a large slum in South India; what does it tell us about managing a pandemic and beyond?,” Epidemiol. Infect., vol. 149, p. e39, Feb. 2021, doi: 10.1017/S0950268821000273.
    OpenUrlCrossRef
  15. [15].
    M. Mohanan, A. Malani, K. Krishnan, and A. Acharya, “Prevalence of COVID-19 In Rural Versus Urban Areas in a Low-Income Country: Findings from a State-Wide Study in Karnataka, India,” medRxiv, p. 2020.11.02.20224782, Nov. 2020, doi: 10.1101/2020.11.02.20224782.
    OpenUrlAbstract/FREE Full Text
  16. [16].
    G. R. Babu et al., “The burden of active infection and anti-SARS-CoV-2 IgG antibodies in the general population: Results from a statewide sentinel-based population survey in Karnataka, India,” Int. J. Infect. Dis., vol. 108, pp. 27–36, Jul. 2021, doi: 10.1016/j.ijid.2021.05.043.
    OpenUrlCrossRef
  17. [17].
    R. Cai, P. Novosad, V. Tandel, S. Asher, and A. Malani, “Representative Estimates of COVID-19 Infection Fatality Rates from Three Locations in India,” medRxiv, Jan. 2021, doi: 10.1101/2021.01.05.21249264.
    OpenUrlAbstract/FREE Full Text
  18. [18].
    S. M. S. Khan et al., “Results of a Population-Based Survey to Estimate the Seroprevalence of SARS-CoV-2 Specific IgG Antibodies in Kashmir, India, Seven Months after the Appearance of the First COVID-19 Case,” Social Science Research Network, Rochester, NY, SSRN Scholarly Paper ID 3820632, Apr. 2021. doi: 10.2139/ssrn.3820632.
    OpenUrlCrossRef
  19. [19].
    S. Sakalle et al., “Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020.,” J. Fam. Med. Prim. Care, vol. 10, no. 3, pp. 1479–1484, Mar. 2021, doi: 10.4103/jfmpc.jfmpc_2015_20.
    OpenUrlCrossRef
  20. [20].
    Tata Institute of Fundamental Research, “SARS-CoV2 Serological Survey in Mumbai by NITI-BMC-TIFR: Preliminary Report of Round-2.” https://www.tifr.res.in/TSN/article/Mumbai-Serosurvey%20Technical%20report-NITI_BMC-Round-2%20for%20TIFR%20website.pdf (accessed Aug. 09, 2021).
  21. [21].
    S. Reporter, “Third sero survey: antibodies in 36.30% samples in Mumbai,” The Hindu, Mumbai, Apr. 25, 2021. Accessed: Aug. 24, 2021. [Online]. Available: https://www.thehindu.com/news/cities/mumbai/third-sero-survey-antibodies-in-3630-samples-in-mumbai/article34404107.ece
  22. [22].
    A. Malani et al., “Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India.,” Lancet Glob. Health, vol. 9, no. 2, pp. e110–e111, Feb. 2021, doi: 10.1016/S2214-109X(20)30467-8.
    OpenUrlCrossRefPubMed
  23. [23].
    M. Banaji, “Estimating COVID-19 infection fatality rate in Mumbai during 2020,” medRxiv, p. 2021.04.08.21255101, Apr. 2021, doi: 10.1101/2021.04.08.21255101.
    OpenUrlAbstract/FREE Full Text
  24. [24].
    “PIB’S BULLETIN ON COVID-19.” https://pib.gov.in/pib.gov.in/Pressreleaseshare.aspx?PRID=1740000 (accessed Aug. 24, 2021).
  25. [25].
    M. V. Murhekar et al., “SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020–January 2021,” Int. J. Infect. Dis., vol. 108, pp. 145–155, Jul. 2021, doi: 10.1016/j.ijid.2021.05.040.
    OpenUrlCrossRefPubMed
  26. [26].
    M. V. Murhekar et al., “SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey,” Lancet Glob. Health, vol. 9, no. 3, pp. e257–e266, Mar. 2021, doi: 10.1016/S2214-109X(20)30544-1.
    OpenUrlCrossRef
  27. [27].
    M. V. Murhekar et al., “Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020,” Indian J. Med. Res., vol. 152, no. 1, p. 48, Jan. 2020, doi: 10.4103/ijmr.IJMR_3290_20.
    OpenUrlCrossRefPubMed
  28. [28].
    G.-A.-U. G.- Öffentlichkeitsarbeit, “COVID-19-Georg-August-Universität Göttingen.” https://www.uni-goettingen.de/en/606540.html (accessed Aug. 24, 2021).
  29. [29].
    S. Purkayastha et al., “Estimating the wave 1 and wave 2 infection fatality rates from SARS-CoV-2 in India,” BMC Res. Notes, vol. 14, no. 1, p. 262, Jul. 2021, doi: 10.1186/s13104-021-05652-2.
    OpenUrlCrossRefPubMed
  30. [30].
    H. Campbell and P. Gustafson, “Inferring the COVID-19 IFR with a simple Bayesian evidence synthesis of seroprevalence study data and imprecise mortality data,” medRxiv, p. 2021.05.12.21256975, May 2021, doi: 10.1101/2021.05.12.21256975.
    OpenUrlAbstract/FREE Full Text
  31. [31].
    R. Bhaduri, R. Kundu, S. Purkayastha, M. Kleinsasser, L. J. Beesley, and B. Mukherjee, “Extending the Susceptible-Exposed-Infected-Removed (SEIR) model to handle the high false negative rate and symptom-based administration of COVID-19 diagnostic tests: SEIR-fansy,” medRxiv, p. 2020.09.24.20200238, Sep. 2020, doi: 10.1101/2020.09.24.20200238.
    OpenUrlAbstract/FREE Full Text
  32. [32].
    A. Banerjee et al., “SARS-CoV-2 Seroprevalence Study in Pimpri-Chinchwad, Maharashtra, India Coinciding with Falling Trend – Do the Results Suggest Imminent Herd Immunity?,” Social Science Research Network, Rochester, NY, SSRN Scholarly Paper ID 3729394, Nov. 2020. doi: 10.2139/ssrn.3729394.
    OpenUrlCrossRef
  33. [33].
    S. Goli and K. S. James, “How much of SARS-CoV-2 Infections is India detecting? A model-based estimation,” medRxiv, p. 2020.04.09.20059014, Apr. 2020, doi: 10.1101/2020.04.09.20059014.
    OpenUrlAbstract/FREE Full Text
  34. [34].
    S. S. Kar, S. Sarkar, S. Murali, R. Dhodapkar, N. M. Joseph, and R. Aggarwal, “Prevalence and Time Trend of SARS-CoV-2 Infection in Puducherry, India, August–October 2020,” Emerg. Infect. Dis., vol. 27, no. 2, pp. 666–669, Feb. 2021, doi: 10.3201/eid2702.204480.
    OpenUrlCrossRef
  35. [35].
    A. Malani et al., “SARS-CoV-2 Seroprevalence in Tamil Nadu in October-November 2020,” medRxiv, p. 2021.02.03.21250949, Apr. 2021, doi: 10.1101/2021.02.03.21250949.
    OpenUrlAbstract/FREE Full Text
  36. [36].
    A. Joshi et al., “Heterogeneous patterns of COVID-19 transmission in an Urban set up – sero-epidemiological survey data from Ujjain, Madhya Pradesh (a central Indian city),” Data Brief, vol. 37, p. 107169, Aug. 2021, doi: 10.1016/j.dib.2021.107169.
    OpenUrlCrossRef
  37. [37].
    M. I. Nisar et al., “Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan.,” Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis., vol. 106, pp. 176–182, May 2021, doi: 10.1016/j.ijid.2021.03.040.
    OpenUrlCrossRef
  38. [38].
    M. Haq et al., “SARS-CoV-2: big seroprevalence data from Pakistan-is herd immunity at hand?,” Infection, pp. 1–6, May 2021, doi: 10.1007/s15010-021-01629-2.
    OpenUrlCrossRef
  39. [39].
    M. G. Ahamad, F. Tanin, B. Talukder, and M. U. Ahmed, “Officially Confirmed COVID-19 and Unreported COVID-19–Like Illness Death Counts: An Assessment of Reporting Discrepancy in Bangladesh,” Am. J. Trop. Med. Hyg., vol. 104, no. 2, pp. 546–548, Feb. 2021, doi: 10.4269/ajtmh.20-1205.
    OpenUrlCrossRef
  40. [40].
    M. G. Ahamad and F. Tanin, “Confirmed and Unreported COVID-19 Death Counts: An Assessment of Reporting Discrepancy,” Jul. 2020, doi: 10.1101/2020.07.20.20158139.
    OpenUrlAbstract/FREE Full Text
  41. [41].
    M. A. A. Al-Bari, S. Hossain, and M. K.-E. Zahan, “Exploration of sex-specific and age-dependent COVID-19 fatality rate in Bangladesh population.,” World J. Radiol., vol. 13, no. 1, pp. 1–18, Jan. 2021, doi: 10.4329/wjr.v13.i1.1.
    OpenUrlCrossRef
  42. [42].
    P. Barnwal et al., “No excess mortality detected in rural Bangladesh in 2020 from repeated surveys of a population of 81,000,” May 2021, doi: 10.1101/2021.05.07.21256865.
    OpenUrlAbstract/FREE Full Text
  43. [43].
    S. K. Dey, M. M. Rahman, U. R. Siddiqi, and A. Howlader, “Exploring Epidemiological Behavior of Novel Coronavirus (COVID-19) Outbreak in Bangladesh.,” SN Compr. Clin. Med., pp. 1–9, Aug. 2020, doi: 10.1007/s42399-020-00477-9.
    OpenUrlCrossRef
  44. [44].
    M. J. Hasan et al., “Clinico-epidemiological characteristics of asymptomatic and symptomatic COVID-19-positive patients in Bangladesh,” medRxiv, p. 2020.08.18.20177089, Aug. 2020, doi: 10.1101/2020.08.18.20177089.
    OpenUrlAbstract/FREE Full Text
  45. [45].
    A. Islam, M. A. Sayeed, M. K. Rahman, J. Ferdous, S. Islam, and M. M. Hassan, “Geospatial dynamics of COVID-19 clusters and hotspots in Bangladesh.,” Transbound. Emerg. Dis., Jan. 2021, doi: 10.1111/tbed.13973.
    OpenUrlCrossRef
  46. [46].
    A. Islam et al., “Spatiotemporal patterns and trends of community transmission of the pandemic COVID-19 in South Asia: Bangladesh as a case study.,” Biosaf. Health, vol. 3, no. 1, pp. 39–49, Feb. 2021, doi: 10.1016/j.bsheal.2020.09.006.
    OpenUrlCrossRef
  47. [47].
    A. U. Khan, A. H. M. Musleh Uddin, F. U. Khan, S. Khanom, and A. U. Khan, “COVID-19: Current Status in Bangladesh,” Jun. 2020, doi: 10.2139/ssrn.3634891.
    OpenUrlCrossRef
  48. [48].
    A. M. M. Mukaddes, M. Sannyal, Q. Ali, and M. T. Kuhel, “Transmission Dynamics of COVID-19 in Bangladesh - A Compartmental Modeling Approach,” Jun. 2020, doi: 10.2139/ssrn.3644855.
    OpenUrlCrossRef
  49. [49].
    Md. R. Rahman, A. H. M. H. Islam, and Md. N. Islam, “Geospatial modelling on the spread and dynamics of 154 day outbreak of the novel coronavirus (COVID-19) pandemic in Bangladesh towards vulnerability zoning and management approaches,” Model. Earth Syst. Environ., Sep. 2020, doi: 10.1007/s40808-020-00962-z.
    OpenUrlCrossRef
  50. [50].
    M. H. B. Siam, M. M. Hasan, S. M. Tashrif, M. H. Rahaman Khan, E. Raheem, and M. S. Hossain, “Insights into the first seven-months of COVID-19 pandemic in Bangladesh: lessons learned from a high-risk country.,” Heliyon, vol. 7, no. 6, p. e07385, Jun. 2021, doi: 10.1016/j.heliyon.2021.e07385.
    OpenUrlCrossRef
  51. [51].
    T. W. Russell et al., “Reconstructing the early global dynamics of under-ascertained COVID-19 cases and infections.,” BMC Med., vol. 18, no. 1, p. 332, Oct. 2020, doi: 10.1186/s12916-020-01790-9.
    OpenUrlCrossRefPubMed
  52. [52].
    E. A. Rana et al., “Molecular detection and prevalence of SARS-CoV-2 during the early outbreak in Southern Bangladesh,” Int. J. One Health, vol. 6, no. 2, pp. 153–159, 2020, doi: 10.14202/IJOH.2020.153-159.
    OpenUrlCrossRef
  53. [53].
    V. S. B. Adapa, S. S. Adapa, and H. Narni, “Andhra Pradesh’s COVID-19 Pandemic Case Fatality Rate,” Jan. 2021, doi: 10.2139/ssrn.3776490.
    OpenUrlCrossRef
  54. [54].
    V. S. B. Adapa, S. S. Adapa, and H. Narni, “COVID-19 Pandemic India’s Case Fatality Rate,” Oct. 2020, doi: 10.2139/ssrn.3687357.
    OpenUrlCrossRef
  55. [55].
    M. Al-arydah, H. W. Berhe, K. Dib, and K. Madhu, “Mathematical Modelling of the Spread of the Coronavirus under Social Restrictions,” medRxiv, p. 2020.09.14.20194068, Sep. 2020, doi: 10.1101/2020.09.14.20194068.
    OpenUrlAbstract/FREE Full Text
  56. [56].
    E. S. Asirvatham, J. Lakshmanan, C. J. Sarman, and M. Joy, “Demystifying the varying case fatality rates (CFR) of COVID-19 in India: Lessons learned and future directions,” J. Infect. Dev. Ctries., vol. 14, no. 10, Art. no. 10, Oct. 2020, doi: 10.3855/jidc.13340.
    OpenUrlCrossRef
  57. [57].
    R. Cai, P. M. Novosad, V. Tandel, S. Asher, and A. Malani, “Representative Estimates of COVID-19 Age-Specific Infection Fatality Rates from Four Locations in India: A Cross-Sectional Observational Study,” Feb. 2021, doi: 10.2139/ssrn.3783787.
    OpenUrlCrossRef
  58. [58].
    P. Chatterjee, “Is India missing COVID-19 deaths?,” Lancet Lond. Engl., vol. 396, no. 10252, p. 657, Sep. 2020, doi: 10.1016/S0140-6736(20)31857-2.
    OpenUrlCrossRefPubMed
  59. [59].
    S. Chatterjee, A. Sarkar, M. Karmakar, S. Chatterjee, and R. Paul, “SEIRD model to study the asymptomatic growth during COVID-19 pandemic in India.,” Indian J. Phys. Proc. Indian Assoc. Cultiv. Sci. 2004, pp. 1–13, Nov. 2020, doi: 10.1007/s12648-020-01928-8.
    OpenUrlCrossRef
  60. [60].
    I. Frost et al., “Risks to Children under-five in India from COVID-19,” medRxiv, p. 2020.05.18.20105239, May 2020, doi: 10.1101/2020.05.18.20105239.
    OpenUrlAbstract/FREE Full Text
  61. [61].
    N. Gonzalez Garcia et al., “Título: COVID-19 pediatric mortality rates are heterogeneous between countries,” Sep. 2020, doi: 10.1101/2020.09.17.20196832.
    OpenUrlAbstract/FREE Full Text
  62. [62].
    M. K. Gupta, P. Bhardwaj, A. D. Goel, S. Saurabh, and S. Misra, “Trends of Epidemiological and Demographic Indicators of COVID-19 in India.,” J. Infect. Dev. Ctries., vol. 15, no. 5, pp. 618–624, May 2021, doi: 10.3855/jidc.13243.
    OpenUrlCrossRef
  63. [63].
    S. Gupta, “The age and sex distribution of COVID-19 cases and fatalities in India,” medRxiv, p. 2020.07.14.20153957, Jul. 2020, doi: 10.1101/2020.07.14.20153957.
    OpenUrlAbstract/FREE Full Text
  64. [64].
    N. Jahan et al., “Entry and initial spread of COVID-19 in India: Epidemiological analysis of media surveillance data, India, 2020.,” Clin. Epidemiol. Glob. Health, vol. 9, pp. 347–354, Mar. 2021, doi: 10.1016/j.cegh.2020.10.008.
    OpenUrlCrossRef
  65. [65].
    S. Kumar, R. Kumar, S. Momani, and S. Hadid, “A study on fractional COVID-19 disease model by using Hermite wavelets,” Math. Methods Appl. Sci., vol. n/a, no. n/a, doi: 10.1002/mma.7065.
    OpenUrlCrossRef
  66. [66].
    M. S. Kumar et al., “National sero-surveillance to monitor the trend of SARS-CoV-2 infection transmission in India: Protocol for community-based surveillance.,” Indian J. Med. Res., vol. 151, no. 5, pp. 419–423, May 2020, doi: 10.4103/ijmr.IJMR_1818_20.
    OpenUrlCrossRef
  67. [67].
    A. Menon, N. K. Rajendran, A. Chandrachud, and G. Setlur, “Modelling and simulation of COVID-19 propagation in a large population with specific reference to India,” medRxiv, p. 2020.04.30.20086306, May 2020, doi: 10.1101/2020.04.30.20086306.
    OpenUrlAbstract/FREE Full Text
  68. [68].
    S. K. Mohanty, U. Sahoo, U. S. Mishra, and M. Dubey, “Age Pattern of Premature Mortality under varying scenarios of COVID-19 Infection in India,” medRxiv, p. 2020.06.11.20128587, Jun. 2020, doi: 10.1101/2020.06.11.20128587.
    OpenUrlAbstract/FREE Full Text
  69. [69].
    S. Mukhopadhyay and D. Chakraborty, “Estimation of undetected COVID-19 infections in India,” May 2020, doi: 10.1101/2020.04.20.20072892.
    OpenUrlAbstract/FREE Full Text
  70. [70].
    S. Naushin et al., “Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2,” eLife, vol. 10, p. e66537, Apr. 2021, doi: 10.7554/eLife.66537.
    OpenUrlCrossRef
  71. [71].
    D. Neve, H. Patel, and H. S. Dhiman, “On Modeling of COVID-19 for the Indian Subcontinent using Polynomial and Supervised Learning Regression,” medRxiv, p. 2020.10.14.20212563, Oct. 2020, doi: 10.1101/2020.10.14.20212563.
    OpenUrlAbstract/FREE Full Text
  72. [72].
    D. Parai et al., “Seroprevalence of anti-SARS-CoV-2 IgG antibody among health care workers of anaesthesia departments from various hospital settings in India,” Mar. 2021, doi: 10.1101/2021.03.20.21253819.
    OpenUrlAbstract/FREE Full Text
  73. [73].
    M. Radha and S. Balamuralitharan, “A study on COVID-19 transmission dynamics: stability analysis of SEIR model with Hopf bifurcation for effect of time delay.,” Adv. Differ. Equ., vol. 2020, no. 1, p. 523, 2020, doi: 10.1186/s13662-020-02958-6.
    OpenUrlCrossRef
  74. [74].
    R. Ranjan, A. Sharma, and M. K. Verma, “Characterization of the Second Wave of COVID-19 in India,” medRxiv, p. 2021.04.17.21255665, Apr. 2021, doi: 10.1101/2021.04.17.21255665.
    OpenUrlAbstract/FREE Full Text
  75. [75].
    J. S and S. Sreedharan, “Analysing the Covid-19 Cases in Kerala: a Visual Exploratory Data Analysis Approach.,” SN Compr. Clin. Med., pp. 1–12, Aug. 2020, doi: 10.1007/s42399-020-00451-5.
    OpenUrlCrossRef
  76. [76].
    P. P. Singh et al., “Estimation of real-infection and immunity against SARS-CoV-2 in Indian populations,” medRxiv, p. 2021.02.05.21251118, Apr. 2021, doi: 10.1101/2021.02.05.21251118.
    OpenUrlAbstract/FREE Full Text
  77. [77].
    A. K. Srivastav, M. Ghosh, and S. R. Bandekar, “Modeling of COVID-19 with limited public health resources: a comparative study of three most affected countries.,” Eur. Phys. J. Plus, vol. 136, no. 4, p. 359, 2021, doi: 10.1140/epjp/s13360-021-01333-y.
    OpenUrlCrossRef
  78. [78].
    V. Tamrakar et al., “District level correlates of COVID-19 pandemic in India,” Oct. 2020, doi: 10.1101/2020.10.08.20208447.
    OpenUrlAbstract/FREE Full Text
  79. [79].
    J. Unnikrishnan, S. Mangalathu, and R. V. Kutty, “Estimating under-reporting of COVID-19 cases in Indian states: an approach using a delay-adjusted case fatality ratio.,” BMJ Open, vol. 11, no. 1, p. e042584, Jan. 2021, doi: 10.1136/bmjopen-2020-042584.
    OpenUrlAbstract/FREE Full Text
  80. [80].
    P. Venkatesan, “Estimate of COVID-19 case prevalence in India based on surveillance data of patients with severe acute respiratory illness,” medRxiv, p. 2020.04.14.20065342, Apr. 2020, doi: 10.1101/2020.04.14.20065342.
    OpenUrlAbstract/FREE Full Text
  81. [81].
    Y. Wang et al., “Estimating the Prevalence and Mortality of Coronavirus Disease 2019 (COVID-19) in the USA, the UK, Russia, and India.,” Infect. Drug Resist., vol. 13, pp. 3335–3350, 2020, doi: 10.2147/IDR.S265292.
    OpenUrlCrossRef
  82. [82].
    A. K. Yadav, S. Ghosh, A. Kotwal, S. Kumar, and S. Bobdey, “Serial antibody response among hospitalized coronavirus disease 2019 cases in India.,” Med. J. Armed Forces India, Nov. 2020, doi: 10.1016/j.mjafi.2020.09.010.
    OpenUrlCrossRef
  83. [83].
    A. A. Z. Ansari et al., “Prevalence and cross states comparison of case fatality rate and recovery rate of COVID 19/SARS-COV-2 in India,” J. Fam. Med. Prim. Care, vol. 10, no. 1, pp. 475–480, Jan. 2021, doi: 10.4103/jfmpc.jfmpc_1088_20.
    OpenUrlCrossRef
  84. [84].
    P. Abraham et al., “Laboratory surveillance for SARS-CoV-2 in India: Performance of testing & descriptive epidemiology of detected COVID-19, January 22 - April 30, 2020,” Indian J. Med. Res., vol. 151, no. 5, pp. 424–437, May 2020, doi: 10.4103/ijmr.IJMR_1896_20.
    OpenUrlCrossRef
  85. [85].
    R. Giri, A. Kumar, M. Saini, and R. K. Sharma, “Living with the virus: Infection and epidemiology of COVID-19 in hotspot area of India.,” J. Public Aff., p. e2651, Feb. 2021, doi: 10.1002/pa.2651.
    OpenUrlCrossRef
  86. [86].
    M. R. T. Shah, T. Ahammed, A. Anjum, A. A. Chowdhury, and A. J. Suchana, “Finding the real COVID-19 case-fatality rates for SAARC countries.,” Biosaf. Health, vol. 3, no. 3, pp. 164–171, Jun. 2021, doi: 10.1016/j.bsheal.2021.03.002.
    OpenUrlCrossRef
  87. [87].
    J. J. M. Wong et al., “Comparative Analysis of Pediatric COVID-19 Infection in Southeast Asia, South Asia, Japan, and China.,” Am. J. Trop. Med. Hyg., Jun. 2021, doi: 10.4269/ajtmh.21-0299.
    OpenUrlCrossRef
  88. [88].
    A. Zaveri and P. Chouhan, “Are child and youth population at lower risk of COVID-19 fatalities? Evidences from South-East Asian and European countries,” Child. Youth Serv. Rev., vol. 119, p. 105360, Dec. 2020, doi: 10.1016/j.childyouth.2020.105360.
    OpenUrlCrossRef
  89. [89].
    R. Bhattacharyya, R. Bhaduri, R. Kundu, M. Salvatore, and B. Mukherjee, “Reconciling epidemiological models with misclassified case-counts for SARS-CoV-2 with seroprevalence surveys: A case study in Delhi, India,” Aug. 2020, doi: 10.1101/2020.07.31.20166249.
    OpenUrlAbstract/FREE Full Text
  90. [90].
    P. Chauhan, A. Kumar, and P. Jamdagni, “Regression Analysis of COVID-19 Spread in India and its Different States,” medRxiv, p. 2020.05.29.20117069, May 2020, doi: 10.1101/2020.05.29.20117069.
    OpenUrlAbstract/FREE Full Text
  91. [91].
    B. S. K. Meghana and V. Kakulapati, “State-wise prevalence of COVID 19 in India by using machine learning approaches,” Int. J. Pharm. Res., vol. 12, no. (Meghana B.S.K., meghanasharma224{at}gmail.com) Chaitanya Bharathi Institute of Technology, Gandipet, Hyderabad, Telangana, India, pp. 2855–2859, 2020, doi: 10.31838/ijpr/2020.SP2.295.
    OpenUrlCrossRef
  92. [92].
    B. Mukherjee, S. Purkayashtha, R. Kundu, and R. Bhaduri, “Estimating the Infection Fatality Rate from SARS-CoV-2 in India,” Mar. 2021, doi: 10.2139/ssrn.3798552.
    OpenUrlCrossRef
  93. [93].
    S. Purkayastha et al., “A comparison of five epidemiological models for transmission of SARS-CoV-2 in India.,” BMC Infect. Dis., vol. 21, no. 1, p. 533, Jun. 2021, doi: 10.1186/s12879-021-06077-9.
    OpenUrlCrossRef
  94. [94].
    V. Patel, C. McCarthy, R. A. Taylor, R. Moir, L. A. Kelly, and E. L. Snary, “An improved methodology for estimating the prevalence of SARS-CoV-2,” medRxiv, p. 2020.08.04.20168187, Aug. 2020, doi: 10.1101/2020.08.04.20168187.
    OpenUrlAbstract/FREE Full Text
  95. [95].
    A. Velumani et al., “SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,” medRxiv, p. 2021.03.19.21253429, Mar. 2021, doi: 10.1101/2021.03.19.21253429.
    OpenUrlAbstract/FREE Full Text
  96. [96].
    N. Gupta et al., “Severe acute respiratory illness surveillance for coronavirus disease 2019, India, 2020,” Indian J. Med. Res., vol. 151, no. 2–3, pp. 236–240, 2020, doi: 10.4103/ijmr.IJMR_1035_20.
    OpenUrlCrossRefPubMed
  97. [97].
    O. Prakash, B. Solanki, J. K. Sheth, M. Kadam, and S. Vyas, “Severe acute respiratory syndrome coronavirus 2 immunoglobulin G antibody: Seroprevalence among contacts of COVID-19 cases.,” Indian J. Public Health, vol. 65, no. 1, pp. 5–10, Mar. 2021, doi: 10.4103/ijph.IJPH_1199_20.
    OpenUrlCrossRef
  98. [98].
    M. Mahto, B. Biswas, A. Banerjee, S. Kumar, N. Agarwal, and P. K. Singh, “Igg seropositivity for sars-cov-2 and its predictors among healthcare workers of Eastern India,” Indian J. Hematol. Blood Transfus., vol. 36, no. 1 SUPPL, p. S112, 2020, doi: 10.1007/s12288-020-01384-8.
    OpenUrlCrossRef
  99. [99].
    A. Malani, M. Mohanan, C. Kumar, J. Kramer, and V. Tandel, “Prevalence of SARS-CoV-2 among workers returning to Bihar gives snapshot of COVID across India,” Jun. 2020, doi: 10.1101/2020.06.26.20138545.
    OpenUrlAbstract/FREE Full Text
  100. [100].
    M. Madhusudan, J. Sankar, K. Dhanalakshmi, S. Putlibai, and S. Balasubramanian, “Seroprevalence to SARS-CoV-2 Among Healthcare Workers in an Exclusive Pediatric Hospital.,” Indian Pediatr., vol. 58, no. 3, pp. 279–280, Mar. 2021, doi: 10.1007/s13312-021-2170-1.
    OpenUrlCrossRef
  101. [101].
    M. Pons-Salort et al., “Reconstructing the COVID-19 epidemic in Delhi, India: infection attack rate and reporting of deaths,” medRxiv, p. 2021.03.23.21254092, Mar. 2021, doi: 10.1101/2021.03.23.21254092.
    OpenUrlAbstract/FREE Full Text
  102. [102].
    S. Siddiqui et al., “SARS-CoV-2 Antibody Seroprevalence and Stability in a Tertiary Care Hospital-Setting,” Oct. 2020, doi: 10.2139/ssrn.3696827.
    OpenUrlCrossRef
  103. [103].
    R. Thiruvengadam et al., “Longitudinal Serology of SARS-CoV-2-Infected Individuals in India: A Prospective Cohort Study.,” Am. J. Trop. Med. Hyg., May 2021, doi: 10.4269/ajtmh.21-0164.
    OpenUrlCrossRef
  104. [104].
    J. Kaushal and P. Mahajan, “Asia’s largest urban slum-Dharavi: A global model for management of COVID-19.,” Cities Lond. Engl., vol. 111, p. 103097, Apr. 2021, doi: 10.1016/j.cities.2020.103097.
    OpenUrlCrossRef
  105. [105].
    M. Mishra, R. Chaudhry, F. Rana, D. S. Nag, and S. Rai, “Serosurveillance of Health Care Workers in a COVID Hospital: Immune Response, and Its Longevity.,” Cureus, vol. 13, no. 3, p. e14020, Mar. 2021, doi: 10.7759/cureus.14020.
    OpenUrlCrossRef
  106. [106].
    S. Kataria et al., “Is Covid-19 seroprevalence different in health care workers as per their risk of exposure? A study from a tertiary care hospital in National Capital Region of India,” Feb. 2021, doi: 10.1101/2021.02.10.21251543.
    OpenUrlAbstract/FREE Full Text
  107. [107].
    S. Ranjan, A. Kaur, and R. Thakur, “Gendered Differentials in Symptoms, Morbidity, and Case Fatality Rate in COVID-19 Pandemic in India: A Study of Karnataka State,” Jun. 2021, doi: 10.2139/ssrn.3865604.
    OpenUrlCrossRef
  108. [108].
    M. S. Khan et al., “SARS-CoV-2 Seroprevalence Among Healthcare Workers by Workplace Exposure Risk in Kashmir, India.,” J. Hosp. Med., vol. 16, no. 5, pp. 274–281, May 2021, doi: 10.12788/jhm.3609.
    OpenUrlCrossRef
  109. [109].
    A. Kumar, D. Sathyapalan, A. Ramachandran, K. Subhash, L. Biswas, and K. V. Beena, “SARS-CoV-2 antibodies in healthcare workers in a large university hospital, Kerala, India.,” Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis., vol. 27, no. 3, pp. 481–483, Mar. 2021, doi: 10.1016/j.cmi.2020.09.013.
    OpenUrlCrossRef
  110. [110].
    H. Kaur, R. Singh, K. Singh, S. Kaur, M. Jairath, and S. K. Sidhu, “Pervasiveness and epidemiological profile of SARS-CoV-2 infection among the population of Majha Region of Punjab,India,” J. Clin. Diagn. Res., vol. 15, no. 6, pp. KC01–KC05, 2021, doi: 10.7860/JCDR/2021/48749.15000.
    OpenUrlCrossRef
  111. [111].
    M. Goenka et al., “Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from India.,” J. Assoc. Physicians India, vol. 68, no. 11, pp. 14–19, Nov. 2020.
    OpenUrlPubMed
  112. [112].
    N. Kumar, S. Bhartiya, S. Desai, A. Mutha, A. Beldar, and T. Singh, “Seroprevalence of Antibodies Against SARS-CoV-2 Among Health Care Workers in Mumbai, India.,” Asia. Pac. J. Public Health, vol. 33, no. 1, pp. 126–128, Jan. 2021, doi: 10.1177/1010539520977307.
    OpenUrlCrossRef
  113. [113].
    N. N. Mahajan et al., “Prevalence and Clinical Presentation of COVID-19 among Healthcare Workers at a Dedicated Hospital in India.,” J. Assoc. Physicians India, vol. 68, no. 12, pp. 16–21, Dec. 2020.
    OpenUrl
  114. [114].
    N. Mahajan et al., “Prevalence, Clinical Characteristics, Virus Clearance and Treatment Outcomes of SARS-CoV-2 Infection in Healthcare Workers in India,” Oct. 2020, doi: 10.2139/ssrn.3706581.
    OpenUrlCrossRef
  115. [115].
    T. Singhal, S. Shah, R. Naik, A. Kazi, and P. Thakkar, “Prevalence of COVID-19 antibodies in healthcare workers at the peak of the pandemic in Mumbai, India: A preliminary study.,” Indian J. Med. Microbiol., vol. 38, no. 3 & 4, pp. 461–463, Dec. 2020, doi: 10.4103/ijmm.IJMM_20_308.
    OpenUrlCrossRef
  116. [116].
    J. Tanna et al., “Incidence and Epidemiological study of COVID-19 in Nagpur urban region (India) using Molecular testing,” medRxiv, p. 2021.05.11.21256719, May 2021, doi: 10.1101/2021.05.11.21256719.
    OpenUrlAbstract/FREE Full Text
  117. [117].
    N. Sharma et al., “The seroprevalence and trends of SARS-CoV-2 in Delhi, India: A repeated population-based seroepidemiological study,” medRxiv, p. 2020.12.13.20248123, Dec. 2020, doi: 10.1101/2020.12.13.20248123.
    OpenUrlAbstract/FREE Full Text
  118. [118].
    R. Gupta et al., “Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers & implications of infection control practice in India.,” Indian J. Med. Res., vol. 153, no. 1 & 2, pp. 207–213, Feb. 2021, doi: 10.4103/ijmr.IJMR_3911_20.
    OpenUrlCrossRef
  119. [119].
    S. M. S. Khan et al., “Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India - A cross-sectional study.,” PloS One, vol. 15, no. 11, p. e0239303, 2020, doi: 10.1371/journal.pone.0239303.
    OpenUrlCrossRef
  120. [120].
    P. S. Satpati et al., “Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur, West Bengal, India,” medRxiv, p. 2020.09.12.20193219, Sep. 2020, doi: 10.1101/2020.09.12.20193219.
    OpenUrlAbstract/FREE Full Text
  121. [121].
    M. Mahto, A. Banerjee, B. Biswas, S. Kumar, N. Agarwal, and P. K. Singh, “Seroprevalence of IgG against SARS-CoV-2 and its determinants among healthcare workers of a COVID-19 dedicated hospital of India.,” Am. J. Blood Res., vol. 11, no. 1, pp. 44–52, 2021.
    OpenUrl
  122. [122].
    P. Bogam et al., “Burden of COVID-19 and Case Fatality Rate in Pune India: An Analysis of First and Second Wave of the Pandemic,” medRxiv, p. 2021.06.21.21259225, Jun. 2021, doi: 10.1101/2021.06.21.21259225.
    OpenUrlAbstract/FREE Full Text
  123. [123].
    A. Ghose et al., “Community prevalence of antibodies to SARS-CoV-2 and correlates of protective immunity in five localities in an Indian metropolitan city,” medRxiv, p. 2020.11.17.20228155, Nov. 2020, doi: 10.1101/2020.11.17.20228155.
    OpenUrlAbstract/FREE Full Text
  124. [124].
    J. Monteiro et al., “Into the thirteenth Month: A Case Study on the Outbreak Analytics and Modeling the spread of SARS-CoV-2 Infection in Pune City, India,” medRxiv, p. 2021.06.22.21259295, Jun. 2021, doi: 10.1101/2021.06.22.21259295.
    OpenUrlAbstract/FREE Full Text
  125. [125].
    S. Sharma, K. Goel, K. K. Kurup, G. S. Grover, and R. Bhaskar, “COVID-19 in Punjab, India: Epidemiological patterns, laboratory surveillance and contact tracing of COVID-19 cases, March-May 2020.,” Clin. Epidemiol. Glob. Health, vol. 11, p. 100769, Sep. 2021, doi: 10.1016/j.cegh.2021.100769.
    OpenUrlCrossRef
  126. [126].
    K. S. Vignesh, V. N. Indhiya Selvan, K. Kosalram, and A. Abarajitha, “A spatial exploratory study on COVID-19 disaster - current outbreak in Tamil Nadu, India,” Turk. J. Physiother. Rehabil., vol. 32, no. 3, pp. 5332–5341, 2021.
    OpenUrl
  127. [127].
    R. Laxminarayan et al., “Epidemiology and transmission dynamics of COVID-19 in two Indian states,” Science, vol. 370, no. 6517, pp. 691–697, Nov. 2020, doi: 10.1126/science.abd7672.
    OpenUrlAbstract/FREE Full Text
  128. [128].
    J. Panchamia, B. Bhagat, V. Bharati, A. Joshi, and D. Mavalankar, “Low COVID-19 mortality in old age homes in western India: an empirical study,” medRxiv, p. 2020.12.08.20245134, Dec. 2020, doi: 10.1101/2020.12.08.20245134.
    OpenUrlAbstract/FREE Full Text
  129. [129].
    A. Suresh and G. N. Srivastava, “Clinicodemographic profile and outcomes of severe COVID-19 infection in young adults,” Indian J. Crit. Care Med., pp. S69–S69, 2021.
  130. [130].
    S. Banerjee, A. Guha, A. Das, M. Nandi, and R. Mondal, “A Preliminary Report of COVID-19 in Children in India.,” Indian Pediatr., vol. 57, no. 10, pp. 963–964, Oct. 2020, doi: 10.1007/s13312-020-2004-6.
    OpenUrlCrossRefPubMed
  131. [131].
    B. B. Basnet et al., “A Year Trend Analysis and Spatial Distribution of COVID-19 Cases in Nepal.,” Asia. Pac. J. Public Health, p. 10105395211012232, May 2021, doi: 10.1177/10105395211012233.
    OpenUrlCrossRef
  132. [132].
    M. L. Dhimal et al., “Age and Gender Differences in COVID 19 Morbidity and Mortality in Nepal.,” Kathmandu Univ. Med. J. KUMJ, vol. 18, no. 72, pp. 329–332, Dec. 2020.
    OpenUrl
  133. [133].
    K. P. Pathak, “COVID-19 in Nepal: Lower Than Expected Incidence and Mortality.,” Asia. Pac. J. Public Health, vol. 32, no. 6– 7, p. 366, Oct. 2020, doi: 10.1177/1010539520940884.
    OpenUrlCrossRef
  134. [134].
    A. K. Sharma et al., “Epidemiological and clinical profile of covid-19 in nepali children: An initial experience,” J. Nepal Paediatr. Soc., vol. 40, no. 3, pp. 202–209, 2020, doi: 10.3126/jnps.v40i3.32438.
    OpenUrlCrossRef
  135. [135].
    S. Abbas, A. Raza, A. Iftikhar, A. Khan, S. Khan, and M. A. Yusuf, “Seroprevalence of SARS-CoV-2 Antibodies Among Health Care Personnel at a Health Care System in Pakistan.,” Asia. Pac. J. Public Health, p. 10105395211011010, Apr. 2021, doi: 10.1177/10105395211011010.
    OpenUrlCrossRef
  136. [136].
    A. Chaudhry et al., “Mortality Analysis of COVID-19 Confirmed Cases in Pakistan,” Jun. 2020, doi: 10.1101/2020.06.07.20121939.
    OpenUrlAbstract/FREE Full Text
  137. [137].
    R. ud Din and E. A. Algehyne, “Mathematical analysis of COVID-19 by using SIR model with convex incidence rate,” Results Phys., vol. 23, p. 103970, Apr. 2021, doi: 10.1016/j.rinp.2021.103970.
    OpenUrlCrossRef
  138. [138].
    O. J. Peter, S. Qureshi, A. Yusuf, M. Al-Shomrani, and A. A. Idowu, “A new mathematical model of COVID-19 using real data from Pakistan,” Results Phys., vol. 24, p. 104098, May 2021, doi: 10.1016/j.rinp.2021.104098.
    OpenUrlCrossRef
  139. [139].
    M. Waqar, B. Wahid, M. Idrees, M. Ali, and Z. Rehman, “Seroprevalence of SARS-CoV-2 in Pakistan: an update on epidemiological trends.,” Z. Naturforschung C J. Biosci., Jun. 2021, doi: 10.1515/znc-2020-0291.
    OpenUrlCrossRef
  140. [140].
    S. Zaidi et al., “Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi-challenges in acquiring herd immunity for COVID 19.,” J. Public Health Oxf. Engl., vol. 43, no. 1, pp. 3–8, Apr. 2021, doi: 10.1093/pubmed/fdaa170.
    OpenUrlCrossRef
  141. [141].
    I. Naiyar, A. F. Anjum, A. M. Khalid, I. Noor, M. S. Abdullah, and M. Z. Anwar, “Seroprevalence of COVID-19 and associated factors in a medical institution in Pakistan.,” J. Taibah Univ. Med. Sci., May 2021, doi: 10.1016/j.jtumed.2021.04.004.
    OpenUrlCrossRef
  142. [142].
    A. Younas, S. Waheed, S. Khawaja, M. Imam, M. Borhany, and T. Shamsi, “Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi, Pakistan.,” Transfus. Apher. Sci. Off. J. World Apher. Assoc. Off. J. Eur. Soc. Haemapheresis, vol. 59, no. 6, p. 102923, Dec. 2020, doi: 10.1016/j.transci.2020.102923.
    OpenUrlCrossRef
  143. [143].
    S. Ali, N. Muhammad, J. Afridi, T. Mehar, N. Mehmood, and Ziauddin, “IgM and IgG antibodies status in suspected patients of Covid-19 in Khyber Pakhtunkhwa, Pakistan,” Med. Forum Mon., vol. 32, no. 4, pp. 120–123, 2021.
    OpenUrl
  144. [144].
    M. Haq et al., “Seroprevalence and Risk Factors of SARS CoV-2 in Health Care Workers of Tertiary-Care Hospitals in the Province of Khyber Pakhtunkhwa, Pakistan,” Sep. 2020, doi: 10.1101/2020.09.29.20203125.
    OpenUrlAbstract/FREE Full Text
  145. [145].
    W. Javed, J. B. Baqar, S. H. B. Abidi, and W. Farooq, “Sero-prevalence Findings from Metropoles in Pakistan: Implications for Assessing COVID-19 Prevalence and Case-fatality within a Dense, Urban Working Population,” medRxiv, p. 2020.08.13.20173914, Aug. 2020, doi: 10.1101/2020.08.13.20173914.
    OpenUrlAbstract/FREE Full Text
  146. [146].
    M. Nisar, Y. Yousafzai, N. Saba, U. Waheed, and M. Khalid, “Seroprevalence of SARS-CoV-2 in blood donors during the second wave of COVID-19 pandemic in Peshawar, Pakistan,” Vox Sang., vol. 116, no. SUPPL 1, pp. 146–147, 2021, doi: 10.1111/vox.13117.
    OpenUrlCrossRef
  147. [147].
    C. Jeewandara et al., “Seroprevalence of SARS-CoV-2 infection in the Colombo Municipality region, Sri Lanka,” medRxiv, p. 2021.06.18.21259143, Jun. 2021, doi: 10.1101/2021.06.18.21259143.
    OpenUrlAbstract/FREE Full Text
  148. [148].
    A. T. Levin, W. P. Hanage, N. Owusu-Boaitey, K. B. Cochran, S. P. Walsh, and G. Meyerowitz-Katz, “Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications,” Eur. J. Epidemiol., vol. 35, no. 12, pp. 1123–1138, 2020, doi: 10.1007/s10654-020-00698-1.
    OpenUrlCrossRefPubMed
Back to top
PreviousNext
Posted September 14, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 infection fatality rates in India: systematic review, meta-analysis and model-based estimation
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 infection fatality rates in India: systematic review, meta-analysis and model-based estimation
Lauren Zimmermann, Subarna Bhattacharya, Soumik Purkayastha, Ritoban Kundu, Ritwik Bhaduri, Parikshit Ghosh, Bhramar Mukherjee
medRxiv 2021.09.08.21263296; doi: https://doi.org/10.1101/2021.09.08.21263296
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 infection fatality rates in India: systematic review, meta-analysis and model-based estimation
Lauren Zimmermann, Subarna Bhattacharya, Soumik Purkayastha, Ritoban Kundu, Ritwik Bhaduri, Parikshit Ghosh, Bhramar Mukherjee
medRxiv 2021.09.08.21263296; doi: https://doi.org/10.1101/2021.09.08.21263296

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (157)
  • Allergy and Immunology (412)
  • Anesthesia (90)
  • Cardiovascular Medicine (852)
  • Dentistry and Oral Medicine (156)
  • Dermatology (97)
  • Emergency Medicine (247)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (392)
  • Epidemiology (8527)
  • Forensic Medicine (4)
  • Gastroenterology (381)
  • Genetic and Genomic Medicine (1731)
  • Geriatric Medicine (166)
  • Health Economics (370)
  • Health Informatics (1232)
  • Health Policy (615)
  • Health Systems and Quality Improvement (465)
  • Hematology (196)
  • HIV/AIDS (367)
  • Infectious Diseases (except HIV/AIDS) (10258)
  • Intensive Care and Critical Care Medicine (550)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (209)
  • Neurology (1662)
  • Nursing (97)
  • Nutrition (247)
  • Obstetrics and Gynecology (321)
  • Occupational and Environmental Health (450)
  • Oncology (918)
  • Ophthalmology (261)
  • Orthopedics (99)
  • Otolaryngology (172)
  • Pain Medicine (110)
  • Palliative Medicine (40)
  • Pathology (249)
  • Pediatrics (532)
  • Pharmacology and Therapeutics (245)
  • Primary Care Research (205)
  • Psychiatry and Clinical Psychology (1751)
  • Public and Global Health (3814)
  • Radiology and Imaging (620)
  • Rehabilitation Medicine and Physical Therapy (316)
  • Respiratory Medicine (518)
  • Rheumatology (204)
  • Sexual and Reproductive Health (164)
  • Sports Medicine (156)
  • Surgery (188)
  • Toxicology (36)
  • Transplantation (99)
  • Urology (74)